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Abstract
CIRCULATING AUTOANTIBODIES IN HUMAN TRAUMATIC SPINAL CORD INJURY
SUBJECTS AND THEIR RELATIONSHIP TO THE DEVELOPMENT OF NEUROPATHIC PAIN

Georgene W. Hergenroeder, M.H.A., B.S.N.
Advisory Professor: Pramod K. Dash, Ph.D.
Background:
Approximately 17,500 spinal cord injuries (SCI) occur yearly in the U.S. causing
considerable morbidity and mortality. Neuropathic pain (NP) ensues in 40-70% of SCI. An
autoimmune response resulting from disruption of the blood-spinal cord-barrier may be a
contributor to NP. However, the relationship between autoantibodies and NP after SCI in
humans has not been thoroughly characterized nor have autoantigens been identified.

Glial

fibrillary acidic protein (GFAP) and collapsin response mediator protein2 (CRMP2) were
identified as candidate autoantigens. The hypothesis is that proteins from the injured spinal
cord released by SCI trigger autoantibody production which can lead to the development of NP.

Results:
The presence of autoantibodies to GFAP (GFAPab) and CRMP2 (CRMP2ab) and their
correlation to the development of NP was evaluated. GFAPab was present in 21 of 38 (55%)
acute SCI, 34 of 80 (43%) chronic SCI. CRMP2ab was present in 8/35 (23%) acute SCI
patient plasma samples.

Complement C3 and C5 were elevated in acute SCI.

Peak

autoantibody levels were detected at 16±7 days post injury. The peak plasma GFAPab levels
were higher in patients that subsequently developed NP versus those who did not (T=219,
p=0.02). Receiver operator characteristic curve analysis shows that plasma GFAPab levels had
an area under the curve of 0.71 (95% CI, 0.53-0.89 p=0.03) for the discrimination of patients
v

that developed NP within 6 months after injury. Patients with GFAPab and/or CRMP2ab had a
9.5 times increased odds of developing NP.

Discussion:
Results show that SCI triggers an autoimmune response leading to production of
autoantibodies. The 16±7 day level of GFAPab post-SCI is a predictor of the development of
NP. The levels of GFAPab returned to levels found in healthy volunteers by 96±54 days postinjury. A panel of GFAPab and CRMP2ab showed 9.5 times increased odds of developing NP
(95% CI, 2.08-43.50, p=0.006).

Future studies will examine the possibility that other

autoantibodies contribute to the development of NP. Measuring GFAPab and CRMP2ab postSCI may help identify patients at risk for subsequently developing NP. A reduction of GFAPab
and/or CRMP2ab in the acute stages of injury may decrease the likelihood for developing NP.

vi

Table of Contents

Approval Sheet..............................................................................................................................i
Title Page......................................................................................................................................ii
Dedication....................................................................................................................................iii
Acknowledgements......................................................................................................................iv
Abstract........................................................................................................................................v
Table of Contents........................................................................................................................vii
List of Illustrations........................................................................................................................xi
List of Tables..............................................................................................................................xiv
Abbreviations..............................................................................................................................xv
Rationale, hypothesis, specific aims and significance.................................................................1
CHAPTER 1. Introduction.........................................................................................................4
1.1 Description and course of spinal cord injury...........................................................................4
1.2 Level and classification of injury (complete or incomplete)....................................................4
1.3 Acute and chronic spinal cord injury.......................................................................................6
1.4 Secondary conditions associated with spinal cord injury.......................................................7
1.5 Innate and adaptive response................................................................................................7
1.6 Autoantibody..........................................................................................................................9
1.7 Neuropathic pain after spinal cord injury..............................................................................11
1.8 Pain pathways......................................................................................................................12
1.9 Mechanisms involved in neuropathic pain............................................................................14
1.10 Autoantibody mediated pain...............................................................................................17
1.11 Knowledge gaps.................................................................................................................17
1.12 Study impact.......................................................................................................................18
CHAPTER 2. General Methods................................................................................................19
vii

2.1 Reagents, antibodies and proteins.......................................................................................19
2.2 Study Subjects.....................................................................................................................22
A. ISNCSCI...................................................................................................................24
B. Classification of neuropathic pain.............................................................................24
2.3 Plasma samples...................................................................................................................25
2.4 Preparation of human cadaver CNS homogenate...............................................................26
2.5 Protein quantitation..............................................................................................................27
2.6 Western blot.........................................................................................................................28
2.7 2-Dimensional gel electrophoresis.......................................................................................29
2.8 Large scale 2-dimensional gel electrophoresis....................................................................32
2.9 LC-MS/MS and protein identification....................................................................................33
2.10 Statistical analysis..............................................................................................................33
2.11 Method to screen for autoantibody detection.....................................................................34
A. Patient samples used for initial autoantibody screening...........................................34
B. Western blots for autoantibody screening................................................................37
2.12 Method to identify antigens for autoantibodies...................................................................39
A. 2-D gel electrophoresis to separate human cadaver CNS protein...........................39
B. Excision of protein spots from 2-D gels....................................................................41
C. LC-MS/MS protein identification...............................................................................43
CHAPTER 3. Human SCI increases autoantibodies to CRMP2...........................................45
3.1 Introduction...........................................................................................................................45
A. Collapsin response mediator protein 2 (CRMP2).....................................................45
B. CRMP2 and neuropathic pain...................................................................................48
3.2 Methods................................................................................................................................49
A. Fluorescent western blots on 2-D gel membranes...................................................49
B. SCI plasma immunoreactivity to purified recombinant CRMP2................................50
C. CRMP2 immunodepletion of brain homogenate......................................................51
viii

D. Capillary electrophoresis-immunoassay...................................................................52
E. Determination of specificity of autoantibodies..........................................................53
F. Analysis of CRMP2ab levels by pain group..............................................................54
3.3 Results.................................................................................................................................54
A. Fluorescent staining validates CRMP2 as a source of immunoreactivity.................54
B. Western blotting confirms T2 SCI plasma immunoreactivity to purified recombinant
CRMP2.....................................................................................................................57
C. Immunodepletion of brain tissue homogenate demonstrates a decrease in T2
plasma immunoreactivity at the molecular weight of CRMP2...................................58
D. Capillary electrophoresis immunoassay is effective at measuring the SCI plasma for
immunoreactivity to CRMP2.....................................................................................59
E. Specificity of immunoreactivity..................................................................................63
E.1 Subjects used in antigen-binding specificity and subsequent studies................63
E.2 Specificity of immunoreactivity to CRMP2..........................................................68
F. No statistically significant difference in the levels of CRMP2ab at 16 ± 7 days in
acute SCI patients who developed neuropathic pain versus those who did not.......71
3.4 Discussion............................................................................................................................73
A. Key findings..............................................................................................................73
B. Spots observed.........................................................................................................73
C. Mechanisms by how CRMP2 autoantibody may contribute to neuropathic pain......74
Chapter 4. Human SCI elicits an autoantibody response to GFAP.....................................75
4.1 Introduction..........................................................................................................................75
A. Astrocytes.................................................................................................................75
B. The role of GFAP......................................................................................................78
C. GFAP is released after CNS injury...........................................................................78
4.2 Methods................................................................................................................................81
A. Spot excision and LC-MS/MS...................................................................................81
ix

B. Validation of GFAP antigen, immunodepletion and western blots............................81
C. Capillary electrophoresis and antigen verification....................................................82
D. Receiver operator characteristic (ROC) curve analysis............................................82
E. Measuring the odds of developing neuropathic pain when GFAPab and/or
CRMP2ab are present at 16 ± 7 days after injury.....................................................84
4.3 Results................................................................................................................................84
A. Spots excised identified as GFAP...........................................................................84
B. Validation of immunoreactivity to GFAP..................................................................85
C. Capillary electrophoresis immunoassay and antigen verification validates the
presence of GFAPab...............................................................................................86
C.1 GFAPab is specific......................................................................................86
C.2 GFAPab is present in plasma samples.......................................................90
C.3 GFAPab in chronic SCI patients does not have diagnostic value for
neuropathic pain................................................................................................95
D. ROC curve analysis shows GFAPab levels distinguish acute patients who develop
neuropathic pain versus those who do not..............................................................95
E. Predictive utility of GFAPab and CRMP2ab for the development of neuropathic pain
after SCI.................................................................................................................100
4.4 Discussion..........................................................................................................................101
A. Key findings..................................................................................................................101
B. There was more than one GFAP spot identified on 2-D gels.......................................102
C. Some healthy volunteers have GFAPab......................................................................103
D. Potential role of GFAP autoantibodies in developing neuropathic pain........................103
Chapter 5. Complement components C3 and C5...............................................................105
5.1 Introduction.........................................................................................................................105
A. What is complement?..............................................................................................105
B. Complement activation and neuropathic pain.........................................................108
x

5.2 Methods..............................................................................................................................110
A. Plasma collection and patient classification............................................................110
B. Enzyme-linked immunosorbent assay (ELISA).......................................................111
5.3 Results...............................................................................................................................112
A. Complement C3 and C5 are activated after SCI....................................................112
B. A correlation is observed between the levels of complement C3 but not C5 with the
levels of GFAPab and CRMP2ab...........................................................................112
C. An association is not found between complement C3 or C5 with the development of
neuropathic pain.....................................................................................................115
5.4 Discussion..........................................................................................................................117
A. Key findings............................................................................................................117
B. Elevation of complement C3 and C5 after SCI.......................................................117
C. No association between complement C3 and C5 levels and neuropathic pain......118
Chapter 6. General Discussion...........................................................................................119
A. Summary of findings..............................................................................................119
B. Weaknesses..........................................................................................................127
C. Model.....................................................................................................................132
D. Future directions....................................................................................................134
E. Study impact on spinal cord injury.........................................................................135
Appendix..................................................................................................................................136
A. Protein A affinity column.........................................................................................136
B. Immunohistochemistry on Monkey brain tissue......................................................139
Bibliography.............................................................................................................................140
Vita..........................................................................................................................................176

xi

List of Illustrations
Figure 1, Flow chart of plasma used for autoantibody screening, validation and association with
neuropathic pain studies............................................................................................................23
Figure 2, 2-Dimensional gel electrophoresis..............................................................................31
Figure 3, Flow chart of methods for autoantibody detection......................................................34
Figure 4, Representative western blot probed with human SCI plasma obtained at T1 and
T2...............................................................................................................................................38
Figure 5, Flow diagram of experiments conducted to identify target antigens...........................39
Figure 6, 2-D gel with human CNS protein and membranes probed with SCI patient
plasma........................................................................................................................................40
Figure 7, Large scale 2-D membranes and Coomassie stained gel showing spots selected for
LC-MS/MS..................................................................................................................................42
Figure 8, Flow chart of immunodepletion of brain homogenate.................................................51
Figure 9, CRMP2 verification, co-localization of immunoreactivity.............................................56
Figure 10, Western blot showing patient plasma at T2 with banding pattern consistent with
positive immunoreactivity to CRMP2 protein..............................................................................57
Figure 11, Decreased immunoreactivity of T2 patient plasma on CRMP2-depleted brain
sample........................................................................................................................................58
Figure 12, Example of assay for CRMP2 plasma dilutions and protein volume.........................60
Figure 13, Capillary electrophoresis immunoassay of patient plasma on CRMP2 protein.........62
Figure 14, Acute (6 month) and chronic SCI S-LANSS scores by pain group...........................66
Figure 15, SCI patient plasma immunoreactivity specific for CRMP2........................................69
Figure 16, CRMP2 Blocking and Competing Studies – SCI Patient non-specific for CRMP2...70
Figure 17, Acute SCI CRMP2ab levels at 16 days are not different by pain group at 6
months........................................................................................................................................72
Figure 18, Model of spinal cord injury showing reactive astrocytes creating a glial
scar.............................................................................................................................................77
Figure 19, Flow chart of GFAP immunodepletion of brain homogenate....................................81
xii

Figure 20, Extrapolation of GFAPab threshold in ng/mL based on GFAPab AUC.....................83
Figure 21, SCI patient plasma immunoreactive to purified recombinant GFAP.........................85
Figure 22, Immunoreactivity of SCI plasma specific for GFAP in response to increasing
amounts of GFAP protein and CRMP2 protein..........................................................................87
Figure 23, SCI patient plasma immunoreactivity specific for GFAP...........................................89
Figure 24, GFAPab levels after SCI over time...........................................................................91
Figure 25, GFAPab levels healthy volunteers vs SCI at 16 days post-injury.............................92
Figure 26, GFAPab levels healthy volunteers vs Chronic SCI...................................................94
Figure 27, Median GFAPab Level by Pain Group over time......................................................96
Figure 28, Acute SCI with Neuropathic Pain had higher GFAPab levels than those without
neuropathic pain.........................................................................................................................97
Figure 29, Receiver operator characteristic analysis of predictive value of GFAPab for the
development of neuropathic pain within 6 months of spinal cord injury.....................................99
Figure 30, Panel of autoantibodies...........................................................................................100
Figure 31, Model of Complement cascade...............................................................................107
Figure 32, Median Complement C3 Acute SCI, Median Complement C5 Acute SCI..............114
Figure 33, Median Complement C3 by Pain Group, Median Complement C5 by Pain Group.116
Figure 34, Model of the presence of autoantibodies at the SCI injury site...............................132
Figure 35, Overview model......................................................................................................133

xiii

List of Tables
Table 1, Methods Table 1, List of reagents or kits....................................................................19
Table 2, Methods Table 2, Antibodies used, provider and catalog number..............................20
Table 3, Methods Table 3, Purified recombinant proteins, provide and catalog number..........21
Table 4, Demographics of Subjects Used in Screening Studies...............................................36
Table 5, LC-MS/MS findings.....................................................................................................44
Table 6, Demographics of subjects used for capillary-immunoassay studies...........................63
Table 7, Demographics of acute SCI patients by pain group....................................................65

xiv

Abbreviations
AD

Alzheimer’s disease

ASIA

American Spinal Cord Injury Association

ATP

Adenosine triphosphate

AUC

Area under the curve

BBB

Blood-brain barrier

BDNF

Brain derived neurotrophic factor

BDP

Breakdown products

bFGF

Basic fibroblast growth factor

BSCB

Blood-spinal cord barrier

C3

Complement component C3

C5

Complement component C5

CALR

Calreticulin

CD

Cluster of differentiation (e.g., CD4+ or CD8+ cells)

Cdk5

Cyclin-dependent kinase 5

CGRP

Calcitonin gene related peptide

CNS

Central nervous system

CRMP2

Collapsin response mediator protein 2

CRMP2ab

CRMP2 autoantibody (determined by immunoreactivity after validation)

CSPG

Chondroitin sulfate proteoglycans

DAMPs

Damage associated molecular patterns

DMSO

Dimethyl sulfoxide

DNA

Deoxyribonucleic acid

EDTA

Ethylenediaminetetraacetic acid

ELISA

Enzyme-linked immunosorbent assay

Fab

Fragment antigen binding; two arms of the antibody molecule that
contain antigen-binding activity

xv

Fc

Fragment crystallizable; constant region of the antibody that does not
bind antigens, interacts with effector molecules and cells.

GABA

Gamma-aminobutyric acid

GFAP

Glial fibrillary acidic protein

GFAPab

GFAP autoantibody (determined by immunoreactivity after validation)

GM1 ganglioside

Monosialotetrahexosylganglioside (prototype ganglioside)

GSK3β

Glycogen synthase kinase-3β

HIV-1

Human immunodeficiency virus-1

HRP

Horseradish peroxidase

IASP

The International Association for he Study of Pain

IEF

Isoelectric focusing

IgG

Immunoglobulin G

IL

Interleukin

IPG

Immobilized pH gradient

IVIG

Intravenous immunoglobulin

ISNCSCI

International Standards for Neurological Classification of Spinal Cord
Injury

LC-MS/MS

Liquid chromatography-mass spectrometry

MAC

Membrane attack complex

MBL

Mannose binding lectin

MBP

Myelin basic protein

microBCA

micro bicinchoninic acid

mRNA

Messenger RNA (ribonucleic acid)

Myc-DDK

Myc tag from the c-myc gene and DDK polypeptide protein tag

NGF

Nerve growth factor

NMDA

N-methyl-D-aspartate

NMO

Neuromyelitis Optica

NP

Neuropathic pain
xvi

P38 MAPK

p38 mitogen-activated protein kinase

PAMPs

Pathogen associated molecular patterns

PBMC

Peripheral blood mononuclear cells

PBST

Phosphate buffered saline with Tween-20

pH

Potential of hydrogen

pI

Isoelectric point

PMSF

Phenylmethane sulfonyl fluoride

PMT

Photomultiplier tube (setting voltage on the Typhoon Trio)

PNS

Peripheral nervous system

PRR

Pattern recognition receptors

PVDF

Polyvinylidene fluoride

RIPA

Radioimmunoprecipitation assay buffer

ROC

Receiver operator characteristic curve

ROS

Reactive oxygen species

S/N

Signal to noise ratio

S-LANSS

Leeds Assessment of Neuropathic Symptoms and Signs

SCI

Spinal cord injury

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

Sema3A

Semaphorin 3A

SLE

Systemic lupus erythematosus

T1

Time 1 (less than 2 days after spinal cord injury)

T2

Time 2 (8-30 days after spinal cord injury)

TBM

Tetramethylbenzidine

TBST

Tris-buffered saline solution containing 1% Tween-20

Tc

Cytotoxic T cells

TGF

Transforming growth factor

Th

Helper T cells
xvii

TNFα

Tumor necrosis factor alpha

TRPV1

Transient receptor potential vanilloid 1 channels

xviii

1. Rationale, Hypothesis, Specific Aims and Significance
Rationale:

Chronic neuropathic pain is a debilitating condition that commonly occurs

after spinal cord injury (SCI). More than half of those with SCI-related neuropathic pain
describe neuropathic pain as their primary problem, more significant than their loss of motor
function.[1] Forty to seventy percent of those with SCI develop neuropathic pain, yet
currently available treatments (e.g., gabapentin and pregabalin) are only partially effective,
and only in some patients.[2] Additionally, there are no predictors of post-SCI neuropathic
pain.[3] A potential contributor to SCI-induced neuropathic pain and inhibitor of recovery is
the autoimmune response to damaged central nervous system (CNS) tissue.
The conditions for an autoimmune response occur as the primary trauma to the
spinal cord disrupts the blood-spinal cord barrier (BSCB). This disruption allows previously
sequestered CNS molecules to enter the systemic circulation where they may elicit an
autoimmune response. Increased permeability of the BSCB also allows circulating immune
cells to infiltrate and access the injury site. The increased access of circulating immune
cells to the injury site initiates the potential for an autoimmune response to ensue.[4]
Rodent models using both rats and mice have demonstrated that SCI can lead to
stimulated T- and B-lymphocyte responses leading to the production of immunoglobulin G
(IgG) autoantibodies to CNS proteins.[5, 6] These IgG autoantibodies from injured subjects
can exacerbate tissue injury by causing ongoing inflammation, hinder recovery and promote
chronic pain. Consistent with this, a study utilizing a constriction model of SCI showed less
mechanical allodynia and hyperalgesia in rats lacking functional T cells compared to
controls.[7] The recognition of antigen by T cells and major histocompatibility complex II
generates inflammatory mediators and facilitates the presence of chronic pain.[8]
Furthermore, SCI in B cell knockout mice that are incapable of generating an antibody
response were shown to have better locomotor function and smaller lesion volume
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compared to SCI wild-type mice.[9] Additionally, injecting purified IgG obtained from SCI
mice into uninjured mice resulted in spinal cord pathology and decreased motor function,
similar to that of the SCI mice.[5]

These studies demonstrate negative effects of

autoimmune responses in rodent models. Relatively few human studies have identified
autoantibodies produced after SCI and, for the most part, these studies have been
performed using directed searches (primarily against myelin proteins, gangliosides and
glycoproteins) limiting their diagnostic and prognostic potential for neuropathic pain.[10-19]
While neuroinflammation is recognized as an ongoing process after SCI, autoantibody
discovery after human SCI has not been thoroughly explored.[20, 21]

Ongoing

inflammation due to an autoimmune reaction to CNS antigens may contribute to
neuropathic pain.
Hypothesis: proteins from the injured spinal cord released by SCI trigger autoantibody
production that can lead to the development of neuropathic pain. Two specific aims are
outlined to test the above hypothesis.
Specific Aim 1: To test whether SCI elicits an autoantibody response and identify the
antigen(s) that triggers this response in human SCI subjects.
Specific Aim 2: To statistically compare whether the presence of autoantibodies to specific
antigen(s) correlates with the development of neuropathic pain in human SCI subjects.
Inflammatory processes such as astrogliosis, abnormal cytokine production
and activation of complement are known to occur after SCI and have been associated with
neuropathic pain.[22-26] Mouse models have identified autoantibodies produced after SCI
to CNS antigens.[27] However, the presence of autoantibodies to CNS proteins in human
SCI has not been well documented, nor have the antigens predictive of neuropathic pain
been established. Western blot-based approaches were utilized to explore the presence of
autoantibodies in human plasma following SCI. Investigations were performed to test for an
association between the presence of the autoantibodies and neuropathic pain. Using this
2

unbiased screening, newly enhanced immunoreactivity to collapsin response mediator
protein 2 (CRMP2) and glial fibrillary acidic protein (GFAP), both CNS antigens, was
detected in patients’ plasma after SCI. Additionally, complement components C3 and C5
were increased in patients’ plasma after SCI. These data suggest that release of CRMP2
and GFAP after SCI may trigger an autoimmune response that contributes to neuropathic
pain.
Further studies were conducted to verify the antigen specificity. The time course of
circulating GFAP autoantibodies (GFAPab), CRMP2 autoantibodies (CRMP2ab) and
complement C3 and C5 levels in SCI patients and whether the presence of GFAPab,
CRMP2ab, C3 or C5 correlated with subsequent development of neuropathic pain was
evaluated. Plasma complement C3 levels at 6.4 ± 1 days and GFAPab at 16 ± 7 days were
correlated; C3 and CRMP2ab levels at 16 ± 7 days were correlated. Analysis identified an
association between the presence of GFAPab at 16 ± 7days post-SCI and the development
of neuropathic pain within 6 months post-SCI. Combining the GFAPab plus CRMP2ab into
a panel determined that the presence of these autoantibodies increased the odds of
developing neuropathic pain 9.5 times compared to those without GFAPab and CRMP2ab
(95% CI, 2.08-43.50, p=0.006). When controlling for age, gender, body mass index,
complete injury, and cervical level, the presence of GFAPab and/or CRMP2ab remained a
significant factor in predicting neuropathic pain within 6 months of SCI (OR 15.3, 95% CI
1.9 to 125, p=0.01).
Significance: These data suggest the autoimmune response to GFAP and CRMP2 is a
contributor to chronic pain following SCI in humans.

If these results are confirmed,

GFAPab and CRMP2ab may be used as a predictor of neuropathic pain. Treatments aimed
at the removal of GFAPab early post-injury may be able to prevent the development of
neuropathic pain. This suggests screening for autoantibody production may initiate new
strategies for preventive therapies.
3

Chapter 1. Introduction
1.1. Description and course of spinal cord injury
Approximately 17,500 SCI occur annually in the U.S.[28]

The World Health

Organization estimates that the worldwide incidence of SCI is up to 500,000/year.
Compared to those without injury, people with SCI are 2 to 5 times more likely to
experience premature death.[29]

Approximately 80% of injuries occur in males.

The

average age at time of SCI is 42 years; 59% of injuries result in tetraplegia (45.8%
incomplete tetraplegia, 13.2% complete tetraplegia), 40.6% paraplegia (20.9% incomplete
paraplegia,19.7% complete paraplegia) and 0.4% are neurologically normal by hospital
discharge.[28] The leading causes of SCI are motor vehicle accidents, falls, assault and
sports-related injuries.
Spinal cord injury can be segregated into two stages, 1) the primary injury from the
initial mechanical insult causing damage to the spinal cord resulting in cell death and the
activation of the inflammatory response; and, 2) the secondary injury caused by the
vascular and immune responses associated with a persistently permeable BSCB. Loss of
function occurs as a result of loss of conduction of sensory and motor signals across the
lesion site. Damage to axons of spinal sensory neurons or dorsal nerve roots causes
interference of ability of afferent signals to reach the brain, and damage to axons of motor
neurons or ventral nerve roots inhibits efferent signals from reaching muscles.

1.2. Level and classification of injury (complete or incomplete)
SCI level of injury is classified according to the most caudal spinal cord segment
(cervical, thoracic, lumbar, or sacral) that is functionally normal. Injury to the cervical spinal
cord results in tetraplegia. Tetraplegia manifests as malfunction of arms, legs, thoracic and
pelvic region. Paraplegia refers to loss of function of thoracic, lumbar or sacral spinal cord
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segments as a result of spinal cord damage. The specific spinal segment injured dictates
the level of function. Paraplegia includes preserved upper extremity function.
SCI degree of neurological impairment is classified as complete or incomplete. A
complete SCI is one in which no motor or sensory function exists below the level of the
lesion. An incomplete injury is one in which some motor or sensory function exists below
the lesion.

The most accepted tool used to classify subjects’ injury is the International

Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) formerly referred
to as the American Spinal Cord Injury Association (ASIA) exam which was based on the
Frankel Classification.[30] The exam captures bilateral upper and lower extremity motor
function based on myotome, and sensory function by dermatome location. Muscle grade is
from 0 (total paralysis) to 5 (active movement against full resistance). Sensory points are
graded as 0 (absent), 1 (impaired) or 2 (normal). In order to be motor incomplete, the SCI
subject must have sacral sparing and either voluntary anal sphincter contraction or motor
function preserved for at least three levels below the motor level. In addition to classifying
the degree of impairment the ISNCSCI assigns motor and sensory levels at the most
caudal segment of the spinal cord where the patient is bilaterally normal. Of note, this is
not necessarily the same as the level of the lesion as it refers to normal function.
Generally, patients’ receive a summary ISNCSCI score based on the spinal segment and
degree of completeness. For instance, a person who has normal motor function and is
able to fully extend their wrist against normal resistance (extensor carpi radialis longus and
brevis, C6) and has normal sensory function to the thumb and index finger, but no function
below that level (complete, A) would be defined as a “C6 A”.

Not all SCI are neatly

classified and a patient’s exam may change over the course of the injury, in part related to
edema/swelling.
Classification is useful as a gauge to measure patients’ improvement or decline in
function, to identify sensory aberrations, to anticipate lifestyle modifications, rehabilitation
5

capability and secondary complications. Patients have varying degrees of recovery related
to the neurological level of injury and degree of impairment. For instance, someone with a
cervical complete injury has less chance of recovery of function and independence, and
more complications than someone with a thoracic incomplete injury.[31] The rate of motor
recovery is highest during the first 3 months and plateaus around 6 months post-SCI.[32]
Ninety-four percent of patients with complete injuries remained complete 1 year to 5 years
post-SCI and, at most, 2% of those with motor incomplete injuries improved
neurologically.[32]
Two recent studies have been performed evaluating the ability of early magnetic
resonance imaging (MRI) biomarker measurements for predicting short term neurological
outcome after cervical and thoracic SCI. Using a data-driven tool, nonlinear principal
component analysis to detect statistical patterns, neurological impairment was predicted

using MRI biomarker measurements demonstrating that the Brain and Spinal Injury Center
(BASIC) score (lesion/no lesion) was predictive for short term outcome (ISNCSCI score at
hospital discharge) for both cervical SCI patients when correcting for interactions from
surgical decompression and spinal cord compression, and thoracic SCI patients.[33, 34]
This type of objective biomarker measurements from imaging or other biological sources
are helpful in classifying injury and in evaluating response to existing and experimental
treatments.

1.3. Acute and chronic spinal cord injury
Damage to the cord begins at the time of trauma and the pathology is progressive.
There is no precise demarcation between the acute and chronic phases of injury.[35] The
distinction is often contextual. Generally, the acute hospital stay when a patient is being
stabilized is considered acute. By the time a patient has lived with an injury for 6 months
the injury is considered in the chronic phase of recovery.[36, 37] During the acute phase of
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injury care focuses on stabilization to prevent further injury and medical management to
prevent secondary complications. Rehabilitation to maximize remaining function is initiated
as the patient recovers. Secondary conditions associated with SCI and their overall health
status affect the injured person’s ability to participate in rehabilitation.

1.4. Secondary conditions associated with spinal cord injury
People with SCI have considerable morbidity including pain (nociceptive and
neuropathic), depression, infections, skin breakdown, deep vein thrombosis, spasticity,
contractures, autonomic dysreflexia, bone demineralization, muscle atrophy, bowel,
bladder and sexual dysfunction in addition to loss of motor and sensory function.[38, 39]
These secondary morbidities contribute to diminished quality of life and reduced life
expectancy.[40-42] The scope of this work focuses primarily on neuropathic pain resulting
after SCI.

1.5.

Innate and adaptive response
The innate immune response is the initial, non-specific immune response which

defends the host against pathogens, eliminates dead or damaged cells and initiates tissue
repair.

This non-specific immune response initiated immediately after SCI causes

vasodilation, edema, cytokine and chemokine production and an influx of leukocytes and
polymorphonuclear cells as the body works to repair damaged tissue.[43] The adaptive
immune response is antigen-specific and therefore requires time to respond. The innate
response is efficient in recognizing specific patterns. For instance, the innate system uses
Pattern Recognition Receptors (PRR) that recognize motifs found on the surface of
bacteria and other pathogens to identify them for destruction. The innate system also
recognizes damage-associated molecular patterns (DAMPS) found on cellular debris and
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initiates its removal.[44] The innate immune response activates the complement system to
enhance antibodies’ and phagocytes’ ability to clear cellular debris and pathogens.[9, 45]
The opsonization (coating) of pathogens by complement facilitates their uptake by
phagocytic antigen presenting cells expressing complement receptors. This readies the
antigen for T cells. Conventional dendritic cells take up antigen in tissue, process it to
generate a peptide antigen that can activate T cells and induce an adaptive immune
response.[46, 47] After SCI, these antigens could be fragments of CNS proteins. There
are two types of antigen-specific lymphocytes, T cells and B cells. B cells are produced in
the bone marrow, have B cell receptors on their surface that are specific for antigens, and
produce antibodies.
The adaptive immune response is induced as T cells and B cells receive antigen
stimulation; T cells differentiate into T effector cells (helper (Th) and cytotoxic (Tc)) and B
cells differentiate into antibody-secreting plasma cells. Activated antigen presenting cells
(dendritic cells) present antigen and prime T cells in peripheral lymph nodes or, as in SCI
with severe inflammation, naïve T cells can be activated within the CNS. [48] Disruption of
gut microbiota is also involved with priming T cells, activation of B cells and autoimmune
responses.[49, 50] T cells are activated and stimulated to release cytokines. CD4+ T cells
secrete cytokines in the CNS; Th1 secrete IFN-γ and Th17 secrete IL-17, IL-21 and IL22.[48] CD8+ T cells secrete TNF-α, IFN-γ.[51] The autoimmune disease systemic lupus
erythematosus (SLE) is associated with antigen presentation by dendritic cells in
association with CD4+ T cells; additionally, CD8+ T cell deficient mice are resistant to the
development of SLE showing T cells can contribute to autoantibody production with
cytokine production.[51]
Mature B cells are released into the circulation and lymphatic system from the bone
marrow as naïve B cells. Upon receiving stimulation from antigen in the presence of Th
cells in lymph nodes a germinal center reaction results in clonal expansion, B cell class
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switching, somatic mutation and the production of 1) activated memory B cells that are
long-lived and 2) plasma cells that secrete antigen-specific antibodies.[48]

1.6. Autoantibody
Antibodies bind specifically to the antigen to generate the immune response and to
recruit cells to destroy the antigen once it is bound by the antibody. Autoantibodies are
antibodies directed against self-antigens. During typical lymphocyte differentiation, some
lymphocytes develop that have affinity for self-antigens. These lymphocytes are removed
or have such low affinity to self-antigens that they are of little significance. A state of selftolerance exists where the immune system does not attack normal self-tissues.
Autoimmunity occurs when this system malfunctions.[52] Autoimmune disease results from
mounting of an immune response to a self-antigen(s). For instance, multiple sclerosis is
the result of auto-reactive T cells against CNS antigens causing the formation of sclerotic
plaques and destruction of myelin sheaths resulting in muscle weakness and ataxia.[53,
54] Pathology occurs when there is a sustained reaction and myelin is destroyed.[55]
Methods of tolerance include the sequestration of antigens where they are not accessible
to the immune system. Trauma that increases the permeability of the BSCB and tissue
damage allowing previously sequestered antigens to become accessible abrogates this
sequestration. The release of CNS antigens can activate ignorant latent T and B cells.
Autoantibodies may be produced by B cells when self-tolerance malfunctions and the body
destroys otherwise normal tissue that the immune system perceives as foreign.[56]
Autoantibody binding triggers B and T cell reactions such as the release of
inflammatory mediators (e.g., IL-1β, IL-6, TNFα, lymphotoxin) that excite nociceptors, or
cause a conformational change or change in expression of receptors or channels, or
induce nerve cell damage resulting in sensitization of nociceptors inducing neuropathic
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pain.[57-61] However, there is controversy about whether autoantibodies produced after
SCI are neuroprotective or neurotoxic. For example, enhancing T-lymphocyte response to
antigens at the injury site has been shown to improve neuronal survival in an optic nerve
injury model.[62] Additionally, intravitreal injection of glutamate or ferrous ions (free
radicals) to nude mice possessing no mature T cells produced significant retinal ganglion
cell loss that was not seen in wild type mice demonstrating neuroprotection from T
cells.[63] A murine retinal ganglion cell study attributed credit to T cells for protection
against thrombin-induced toxicity because of T cells’ ability to transcribe thrombin inhibitor
anti-thrombin III.[64] It was previously demonstrated that after crush injury, retinas of rats
treated with the thrombin inhibitor NAPAP (N-α-(2-naphthylsulphonylglycyl)-4-(D,L)amidinophenylalanine piperidide acetate salt) had more intact retinal ganglion cells
compared to vehicle treated rats.[65]
Efforts to utilize the immune response in order to induce neuroprotection after SCI
are under study. Nogo is an axonal growth inhibitor protein.

Anti-Nogo-A antibodies

infused intrathecally have facilitated axon regeneration in rats and monkeys.[66] It has
been proposed that the anti-Nogo-A antibody induces T cell mediated neuroprotection.[67]
A safety and feasibility clinical trial of humanized anti-Nogo-A antibody (Novartis
Pharmaceuticals) was recently conducted in 52 acute SCI patients; the results are
pending.[68]
Alternatively, antibodies created in response to myelin damage at the site of injury
are believed to result in secondary damage.[6] Myelin basic protein (MBP) is a major
structural protein in myelin. MBP-reactive T cells propagate the inflammatory process by
producing cytokines. Chronic SCI patients have been shown to have high levels of MBPreactive T cells.[69] GM1 ganglioside-specific autoantibodies, as well as cytokines IL-2
and TNFα, which promote axonal dysfunction and demyelination, were elevated in chronic
SCI patients.[19]
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1.7. Neuropathic Pain after Spinal Cord Injury
Pain serves a protective function in that it signals the body to prevent or notifies the
body of tissue injury. Virtually all patients experience pain due to trauma after an SCI.
However, neuropathic pain is a distinct type of pathological pain that persists after wound
healing.

Prevalence rates of neuropathic pain after SCI range from 26% to 96% of

patients.[3] Using more consistent definitions of neuropathic pain the estimated range is
narrowed to 40% - 70% of SCI patients. [2, 70, 71]

Once neuropathic pain occurs it tends

to become chronic.
Neuropathic pain is defined as “pain caused by a lesion or disease of the
somatosensory system”.[70, 72, 73] The current definition was derived from the
International Association for the Study of Pain (IASP) that defined neuropathic pain as
“pain arising as a direct consequence of a lesion or disease affecting the somatosensory
system”.[74] The IASP proposed a uniform classification system to define pain: nociceptive
(musculoskeletal and visceral) and neuropathic (at level and below level of injury). The
International Spinal Cord Injury Pain Classification system offers a tiered system of
classification of pain types.[70] In addition to necessitating a CNS lesion, these neuropathic
pain definitions include characteristics requiring that 1) sensory deficits exist within the pain
distribution; 2) allodynia and/or hyperalgesia exist within the pain distribution and 3) the
patient verifies that neuropathic pain descriptors (e.g., hot-burning, tingling, pins and
needles, etc.) depict their pain. In contrast, musculoskeletal pain is characterized as a dull
aching pain that gets worse with movement, and is often related to overuse injuries (i.e.
transfers relying on only arm and shoulder muscles).
Pain limits physical function and ability to rehabilitate, infringes on work and social
activities, and reduces quality of life. Approximately 75% of SCI patients with neuropathic
pain described it as a sharp, shooting continuous pain that is stimulus-independent; it is
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associated with allodynia (normally non-painful stimuli evoking pain), hyperalgesia
(increased sensitivity to noxious stimuli), and paresthesia (pins and needles sensation).[2]
The factors that are associated with, or causal of, the development of chronic neuropathic
pain in SCI have not been fully determined.
Neuropathic pain and spasticity (exaggerated muscle tone with increased tendon
reflexes and clonus) are both aftereffects of maladaptive neuronal plasticity resulting from
injury, but musculoskeletal pain due to spasticity differs from neuropathic pain and is
differentiated through careful assessment.[75] Multiple factors including psychological, pain
location, pain descriptors and onset, injury characteristics, physical condition

and

environment must be taken into account when evaluating pain.[75] Distinguishing the type
of pain experienced after SCI (neuropathic, nociceptive, or other) is important in
determining the appropriate treatment. Unfortunately, neuropathic pain is frequently
refractory to existing treatments.[76-78] Gabapentin and pregabalin, commonly used
medications for SCI neuropathic pain,

provide partial relief.[79, 80] In addition to

unsatisfactory pain relief, existing treatments have undesirable side effects.[81] For
example, these medications are known to cause drowsiness, weakness, fatigue, cognitive
issues, constipation, dry mouth and headache. It is difficult to predict which SCI patient is
at risk for developing neuropathic pain. Notwithstanding the above definition of neuropathic
pain there is no universally accepted objective test for diagnosing neuropathic pain, and a
clinical diagnosis of neuropathic pain remains the standard on which most tools are
based.[70, 82-84] There are ongoing international efforts for standardizing the definition
and grading of neuropathic pain.[70, 77, 83, 84]

1.8. Pain Pathways
Pain is sensed by specialized sensory receptors (nociceptors) that transmit signals
from noxious stimuli along A delta (Aδ) and C fibers to the dorsal horn of the spinal cord.
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Thermoreception is also transmitted through Aδ and C fibers. There are three types of
primary afferent nerve fibers, Aδ, C and Aα/β fibers.

Aα/β fibers are large diameter

myelinated fibers that have a low threshold for activation and conduct signal rapidly and
transmit non-noxious stimuli/mechanoreception.[85] Aδ fibers transmit sharp, fast pain.
They are small diameter myelinated fibers.
therefore slow conducting.

C fibers are unmyelinated and small and

They carry dull, long lasting pain and are responsible for

perceiving burning pain. Most primary afferent fibers enter the spinal cord through dorsal
roots at their level of origin or 1-2 segments above or below, although some unmyelinated
afferent fibers enter the spinal cord though ventral roots.[85] Generally, C fibers terminate
in laminae 1-2 and Aδ fibers in laminae 1, 2, 5 and 6. [85] The major pathways that
transmit pain signals are the spinothalamic tract and the spinoreticular tract. Secondary
afferent fibers decussate close to the level of entry and ascend on the contralateral
spinothalamic tract to the thalamus to third order neurons which end in the somatosensory
cortex. The spinoreticular tract is implicated in the emotional component of pain; it also
ascends on the contralateral side and after reaching the reticular formation of the
brainstem goes to the thalamus and hypothalamus and then to the cortex. There are
descending pathways that inhibit pain transmission, these are central to Melzack and
Wall’s gate control theory of pain sensation, and the ascending/descending pain
transmission system.[86, 87] The gate control theory proposes that non-noxious sensory
input from Aα/β fibers activates inhibitory neurons which inhibit pain transmission (input
from the C or Aδ fibers). The gate is opened or closed depending on the balance of the
large (Aα/β) and small (C or Aδ) fiber input; prolonged high-intensity stimulation disturbs
the balance which results in removal of presynaptic inhibition of sensory inputs and opens
the gate. The gate control theory proposes that peripheral sensory and central inputs
cause brain activity to reach a threshold evoking pain.[87] The ascending/descending pain
transmission system is made up of areas that have high concentrations of opioid receptors
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and endogenous opioids; descending pathways project to the dorsal horn using
noradrenaline and serotonin to inhibit pain. The system includes the upper brain stem
periaqueductal gray matter, the locus coeruleus the nucleus raphe magnus and nucleus
reticularis gigantocellularis.[88] Pain perception and processing occurs in multiple areas of
the brain including the thalamus, the somatosensory, insular, anterior cingulate, and
prefrontal cortex. Multiple mechanisms are involved in the development and maintenance
of neuropathic pain.

1.9. Mechanisms involved in neuropathic pain
Injury to the spinal cord results in damage and disruption of the pathways that
transmit signals from peripheral sensory receptors to the dorsal horn of the spinal cord and
then ascend to the brain.

Studies in animals have identified multiple mechanisms

contributing to the development or maintenance of neuropathic pain, however these
mechanisms are not fully understood.[89] Neuropathic pain mechanisms can be
interrelated. These include increased spontaneous activity of pain nociceptive neurons,
sprouting of C and Aδ fibers, altered expression of ion channels on neurons in the pain
pathway, removal of inhibitory inputs, altered release and reuptake of the excitatory
neurotransmitter glutamate, altered expression of excitatory neurotransmitter receptors,
increased efficacy of “silent synapses” or newly formed synaptic circuits and synaptic
reorganization, and increased firing of dorsal root ganglion neurons.[90-101]

These

mechanisms do not occur in isolation, and central components of developing neuropathic
pain include neuronal hyperexcitability and inflammation.[102, 103]
Peripheral sensitization (enhanced response to stimuli by the nociceptor) and
central sensitization (enhanced response to painful stimuli in the spinal cord dorsal cord
neurons) can occur after SCI.[104] Previously silent nociceptive neurons become
responsive after a prolonged period of stimulation, and nociceptive neurons are exposed to
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excitatory neurotransmitters including substance P and calcitonin gene-related peptide
creating peripheral sensitization and pain.[105-109]

Peripheral sensitization causes

increased frequency of nerve impulses leading to hyperexcitability from prolonged release
of glutamate in the dorsal horn and subsequent central sensitization and pain.[104]
Neuronal hyperactivity, defined as enhanced spontaneous neuronal excitability or
enhanced neuronal responses to sensory stimuli resulting in pain hypersensitivity, is
essential for the development and maintenance of neuropathic pain. [110] In a study of 15
people with complete thoracic SCI at-level hypersensitivity to cold, touch and pinprick was
associated with neuropathic pain.[111] After SCI multiple alterations can occur causing
neuronal hyperexcitability in the dorsal horn resulting in neuropathic pain.[104] Using a
sensorimotor test to evaluate mechanical allodynia in rodents, correlations have been
found between neuronal hyperactivity and neuropathic pain

as demonstrated by 1)

decreased threshold for paw withdrawal with simultaneous increased firing of the dorsal
horn sensory neurons and 2) increase in ion channel expression with neuropathic pain
behaviors.[110]
Inflammation in the spinal cord which leads to secondary tissue damage is an
important contributor to neuropathic pain.[112, 113] CNS glial cells (microglia, astrocytes
and oligodendrocytes) are involved in the initiation and continuation of neuropathic pain.
For instance, blocking glial activation in rats prevented neuronal and glial activation of a
phosphorylated MAPK (p38 MAPK) and reduced neuronal hyperexcitability and
mechanical allodynia.[104, 114] Glial cell activation has also been identified in human
spinal cord tissue. A study of post-mortem human spinal cords including 11 SCI and 2
traumatic brain injury (TBI) control spinal cords evaluated spinal cord tissue obtained from
people who died 30 minutes to 5 days post-SCI. Activated microglia, IL-1β, IL-6 and
TNFα, all associated with inflammation, were found near the lesion and in the spinal cord
as early as 30 minutes post-SCI, but no expression was found in the spinal cords of people
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who died secondary to TBI without SCI.[115]

Serum levels of IL-6, and TNFα were

elevated in people with SCI and these cytokines were further elevated in people with pain
or who had active infection.[16] The presence of inflammatory mediators and the fact that
blocking them alleviates pain provides support for inflammation as a mechanism for
neuropathic pain.
Activated

astrocytes

and

microglia

release

pro-inflammatory

cytokines,

neurotransmitters, and reactive oxygen species (ROS). This results in increased bloodspinal cord barrier (BSCB) permeability, and abnormal function of ion channels and
receptors. Activation of voltage-gated calcium channels and NMDA receptors result in an
increase in intracellular calcium ions, this leads to activation of multiple downstream kinase
pathways (e.g., calcium-calmodulin-dependent kinase II, protein kinase C, protein kinase
A) which perpetuate neuronal hyperexcitability of dorsal horn sensory neurons.[110]
Glial cells, including microglia and astrocytes are involved in hyperexcitability and
neuropathic pain. Glial cells maintain gamma-aminobutyric acid (GABA) and glutamate
concentrations in the spinal cord contributing to both release and uptake in order to
maintain extracellular concentrations.[89] GABA is a neurotransmitter that acts on
inhibitory interneurons; loss of GABA inhibition results in hyperexcitability in dorsal horn
neurons and neuropathic pain.[89, 116]
contributes to sensitization.

Glutamate, an excitatory neurotransmitter,

After painful stimuli, intracellular calcium concentration

increases in astrocytes which in turn cause an increase in calcium-dependent glutamate.
High intracellular calcium concentrations activate phospholipase A2.[104]

Arachidonic

acid, prostaglandins and leukotrienes are produced when phospholipase A2 hydrolyzes the
cell membrane. Calcium-independent phospholipase A2 produces reactive nitrogen
species, MAPK, and ROS.[104] ROS cause the release of glutamate via the Transient
receptor potential vanilloid 1 (TRPV1) and TRPA1 channels which are also involved with
neuropathic pain.[104, 113] Glutamate release increases local glutamate receptors and
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ion channels which in turn increases the release of cytokines and ROS and activation of
glial cells and kinase cascades leading to pain.[89]

1.10. Autoantibody mediated pain
Autoantibodies to CNS proteins can elicit pain via multiple mechanisms.
Complement binding of the Fc region of autoantibodies can produce inflammation, when
this inflammation causes nerve damage neuropathic pain can occur.[45, 57, 117] For
instance, complement-induced response ultimately leads to neuronal damage and can
cause neuropathic pain as is found in Guillain-Barre syndrome.[57] Autoantibodies binding
to nociceptors may damage the nerve cell or change its function resulting in neuropathic
pain.[57] Sensitized nociceptors may become hypersensitive to noxious and/or nonnoxious stimuli or become spontaneously active. Neuropathic pain mediated through Fabregion binding can have multiple effects by blocking the binding sites, causing a
conformational change, or activating the antigen.[57] The binding of the antigen by the
antibody may potentiate the inflammatory response and/or prevent the glial scar from
forming properly perpetuating a permeable BSCB and neuropathic pain.[25]
Autoantibodies produced after SCI could work through any of these means and
result in the development of neuropathic pain. Currently, there are no diagnostic tools
available to predict who will develop chronic neuropathic pain after SCI. Therefore, this
research sought to identify autoantibodies after SCI that may predict the development of
neuropathic pain.

1.11. Knowledge Gaps.
Although both experimental and clinical studies have observed immune responses
after SCI, it has not been investigated if human SCI elicits an autoantibody response. As a
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part of this thesis research the following questions were investigated in human SCI
subjects:
1. Does human SCI elicit an autoantibody response?
2. What is the antigen(s) that triggers autoantibody production?
3. Does the circulating level of identified autoantibodies correlate with the development or
presence of neuropathic pain?

1.12. Study Impact
The identification of autoantibodies produced after SCI may lead to new treatment
targets or new prognostic indicators.

Hypothesis: proteins from the injured spinal cord released by SCI trigger autoantibody
production that can lead to the development of neuropathic pain.

Aim 1: To test whether SCI elicits an autoantibody response and identify the antigen(s)
that triggers this response in human SCI subjects.

Aim 2: To statistically compare whether the presence of autoantibodies to specific
antigen(s) correlates with the development of neuropathic pain in human SCI subjects.
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Chapter 2. General Methods
2.1. Reagents, antibodies and proteins
Methods Table 1. List of reagents or kits
Reagent or Kit

Provider

Catalog Number

CDP-Star Reagent for alkaline

Biolabs, Ipswich, MA

C0712

Sigma Aldrich

A7906-100G and A3059-

phosphatase
Albumin from Bovine Serum

50G
microBCA assay kit

Thermo Scientific,

23235

Rockford, IL
Melon Gel IgG Spin

Thermo Scientific,

Purification kit (Antibody

Rockford, IL

45206

purification)
Pierce Protein A IgG Plus

Thermo Scientific,

Orientation (protein A affinity

Rockford, IL

44893

columns)
Complement C3 ELISA

abcam

ab108822

Complement C5 ELISA

abcam

ab125963

Precision Plus Protein

BioRad

161-0363

Standards
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Methods Table 2. Antibodies used, provider and catalog number.
Antibody

Provider

Catalog Number

Custom rabbit anti-GFAP antibody

Custom – Dash lab

NA

Anti-CRMP2 (Rabbit)

Sigma Aldrich

C2993

Anti-CRMP2 antibody(Rabbit)

abcam

Ab36201 Rb,

Primary Antibodies

Lot GR212945-1
Anti-CRMP2 antibody (Rabbit)

ThermoFisher

PA5-29728

Scientific
Secondary Antibodies
Goat anti-human IgG (H+L)

Invitrogen by

secondary antibody, Alexa Fluor

Thermo Fisher

488 conjugate

Scientific

Goat anti-human IgG (H+L)

Invitrogen by

seconday antibody, Alexa Fluor

Thermo Fisher

568 conjugate

Scientific

Alkaline phosphatase goat anti-

Vector

rabbit IgG antibody
HRP goat anti-human IgG

A-11013

A-21090

AP-1000 anti-R,
Lot YO222

Vector

antibody (peroxidase)

PI-3000,
Lot ZA0709

Pierce Antibody Goat Anti-Rabbit

Pierce Thermo

Prod #31460,

IgG (H+L) Horseradish Peroxidase

Scientific

Lot OG 1886-49

Anti-rabbit horseradish peroxidase

Protein Simple

DM-001,

secondary antibody for Wes

Lot number 26571
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Methods Table 3. Purified Recombinant Proteins, Provider and Catalog number
Protein

Provider

Catalog

Predicted

Reference peptide

Number

Molecular

sequence

Weight
(kDa)
Purified recombinant protein

OriGene

TP304548

49.7

NP_002046

OriGene

TP309080

62.1

NP_001377

OriGene

TP303222

46.4

NP_004334

of human glial fibrillary acidic
protein (GFAP), transcript
variant 1

Purified recombinant protein
of homo sapiens
dihydropyrimidinase-like 2
(DPYSL2)

(CRMP2)

Recombinant protein of
human calreticulin
(CALR)
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2.2. Study Subjects
The protocol for the use of adult human subjects was reviewed and approved by the
University of Texas Committee for the Protection of Human Subjects. All SCI subjects
enrolled were over 18 years of age and had a traumatic, non-penetrating SCI with a
neurologic deficit. Acute SCI subjects were enrolled within 2 days of SCI. Chronic SCI
subjects were enrolled at greater than one year post-injury. Subjects were excluded if they
had a known medical condition that accounted for neuropathic pain (e.g., diabetic
neuropathy, renal insufficiency, HIV-associated, ethanol-associated neuropathy) or
diagnosis of cancer within the previous 5 years. In addition, chronic SCI subjects were
excluded if they had a known infection within 30 days of blood sampling. Blood samples
were obtained after informed consent and were de-identified to provide confidentiality.
Plasma from healthy volunteers was used as reference controls.

Plasma from these

groups of patients was used for autoantibody screening, validation and association with
neuropathic pain studies (Figure 1).

Demographic and clinical data were collected.

Patients’ neurological levels of injury were classified according to the ISNCSCI Scale.[30]
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Figure 1. Flow chart of plasma used for autoantibody screening, validation and association
with neuropathic pain studies.

Flow chart of subjects and samples used for autoantibody screening; T1= Time 1
(within 2 days after SCI); T2=Time 2 (8-30 days after SCI).
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A. ISNCSCI
The ISNCSCI is a standardized method of classifying sensory and motor impairment
in spinal injury for research and clinical practice.[30] Subjects enrolled in this study were
ISNCSCI A-D defined as,
“A = Complete. No sensory or motor function is preserved in the sacral segments
S4-S5.
B = Sensory Incomplete. Sensory but not motor function is preserved below the
neurological level and includes the sacral segments S4-S5 AND no motor function is
preserved more than three levels below the motor level on either side of the body.
C = Motor Incomplete. Motor function is preserved below the neurological level, and
more than half of key muscle functions below the single neurological level of injury
have a muscle grade less than 3.
D = Incomplete. Motor function is preserved below the neurological level, and at
least half of key muscles below the neurological level have a muscle grade greater
than or equal to 3.”[30]
American Spinal Injury Association: International Standards for Neurological Classification of Spinal Cord Injury

B. Classification of Neuropathic Pain
The definition of neuropathic pain was based on the clinical diagnosis and
documentation of neuropathic pain.

In order for a subject to be classified as having

neuropathic pain there must have been documentation of pain in the medical record which
included the descriptor neuropathic.

The IASP has proposed a uniform classification

system to define pain: nociceptive (musculoskeletal and visceral) and neuropathic (at level
and below level of injury).[118] In accordance with the IASP and other recommendations,
pain documented as “acute pain due to trauma” was not considered neuropathic pain nor
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was nociceptive pain described as musculoskeletal, visceral or headache considered
neuropathic.[119] Treatment with gabapentin or pregabalin, commonly used medications for
neuropathic pain, was used as confirmation of the neuropathic categorization.

All of the

chronic and 18 of the acute subjects completed the Leeds assessment of neuropathic
symptoms and signs (S-LANSS) pain scale and the Short-Form McGill Pain Questionnaire
as additional validation of their pain classification.[120-122] The S-LANSS scale has been
validated against clinical judgement.[121]

These scores were corroborated with the

clinician’s assessment of pain. The S-LANSS self-assessment form was administered in a
standardized manner. Subjects were instructed to consider their pain within the last week
and to focus on the most severe pain. The instrument includes a numeric visual analog
scale for rating pain intensity and diagram on which the subject indicates where the
neuropathic pain exists. Descriptors on the S-LANSS and in the McGill Pain Questionnaire
include words commonly associated with neuropathic pain (e.g., pins and needles, electric
shock, burning). The pain onset, duration, aggravating or mitigating factors and whether or
not the patient had spasticity was also documented.

2.3. Plasma Samples
For the initial screening for autoantibodies, blood samples were collected in EDTA
tubes (BD, Franklin Lakes, NJ USA) from 18 adult, acute, traumatic SCI patients at two time
points: 1) within 2 days of injury (Time 1, T1); and, 2) within 8-30 days of injury (Time 2,
T2). A study has demonstrated that IgG titers peaked 14-33 days after brain injury [123],
therefore, it was anticipated that autoantibodies related to injury would not be present close
to time of injury and would emerge within the Time 2 period. Blood cells were removed by
centrifugation (4°C, 800 X g for 10 minutes), plasma was collected, and platelet-poor
plasma prepared by centrifugation (4°C, 10,000 X g) for 10 min. Samples were aliquoted
and frozen at -80oC until assayed.
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To confirm the presence of autoantibodies to a specific CNS protein, plasma was
collected and processed in the same manner as described above for acute and chronic SCI
patients and healthy volunteers. Autoantibody confirmatory studies were performed on
plasma obtained from 38 adult, acute, traumatic SCI patients at four time points post-injury:
1.2 ± 0.7, 6.4 ± 1, 16 ± 7 and 96 ± 54 days post-injury. Thirteen of these subjects provided
the sample at 96 ± 54 days post-SCI. The 80 chronic SCI subjects (> 1 year post-SCI) and
20 healthy volunteers provided a one-time blood sample.

2.4. Preparation of Human Cadaver CNS Homogenate
It is not possible or humane to obtain CNS tissue samples from individual patients to
test for IgG reactivity to self-proteins. For the purpose of this study, human cadaver CNS
tissue was used as a substitute for the patient’s own tissue and antibodies produced in
response to this tissue were classified as autoantibodies.

Human cadaver CNS tissue

samples (from one individual who died from complications of Alzheimer’s disease (AD)) and
three individuals without confirmed AD were obtained from the UT-Health Willed Body
Program and were frozen at -80°C until ready for use. The mean time from time of death to
tissue extraction was 16 hours. Cadaver tissue was collected from an 1) elderly male with
a medical history of AD, cluster headaches, and concussion in 1965 after being hit by a car
while riding a bike. 2) A 75 year old female with possible history of dementia, post-mortem
interval from time of death until tissue extraction was less than 24hrs. 3) A 75yo male with
history of cardiac bypass, post-mortem interval was approximately 14 hours until tissue
procurement; and 4) A 67 year old female with post-mortem interval of 12 hours. The
subject appeared to be of low to normal body weight, no medical history was provided.
CNS tissue from the four cadavers listed above was used for 1- and 2Dimensional (1-D and 2-D) gel studies. The rationale for use of multiple sources of CNS
tissue was to assure that anti-mortem factors from any one cadaver and/or post-mortem
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time did not dictate study results.[124] For instance, glial cells and specifically, astrocytes
have been associated with Alzheimer’s disease (AD). [125] Post-translational changes,
including glycosylation, phosphorylation and increased GFAP expression have been
reported in the AD brain. [126] Increased CRMP2 phosphorylation is present in the AD
brain.[127] As the initial cadaver donor had AD, to assure that reactivity to the CNS
homogenate was not specific to post-translational changes with one specific homogenate
donor, testing was performed using different donors who did not have AD. Experiments on
both 1-D and 2-D gels were repeated with brain homogenate from 4 different cadaver
donors, only one of which had a reported clinical diagnosis of AD. The latter 3 cadaver
brains were perfused with PBS prior to CNS tissue procurement. Cadaver CNS tissue was
snap frozen in liquid nitrogen which causes rapid, temporary inactivation of all reactions that
occur in extracted tissue.[128] Neural tissue is sensitive to protein degradation (for instance
degradation fragments) which could impact CRMP2 or GFAP proteins; however, no
degradation was seen in post-mortem interval analysis of GFAP.[124, 128]
CNS

tissue

samples

were

homogenized

in

a

buffer

consisting

of

radioimmunoprecipitation assay buffer (RIPA) containing protease (1mM PMSF in DMSO;
10 µg/ml leupeptin hemisulfate) and phosphatase (1 mM NaF; 0.2 mM Na pyrophosphate,
100 nM okadaic acid in DMSO). Protein concentration was estimated using a microBCA
assay kit (Thermo Scientific) and tested on western blot as described below. Results from
samples from spine tissue were replicated in brain tissue. Because brain tissue was more
accessible the western blot experiments discussed below were conducted using brain
tissue homogenates (total human CNS protein).

2.5. Protein quantitation
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A microBCA assay kit (Thermo Scientific) was used to quantify protein
concentrations in CNS protein/brain homogenate samples. Bicinchoninic acid (BCA) was
used as the detection reagent of Cu++. Cu++ is formed when Cu2+ is reduced by protein
in an alkaline setting. A standard curve with 6 serial dilutions was made in duplicate using
bovine serum albumin (BSA). Two hundred microliters of the protein assay mix of reagents
MA, MB, MC (combined in the ratio of 25:24:1) were applied to each well. Standards, plain
buffer, and unknowns were applied to a 96 well plate and allowed to incubate for 45
minutes. The results were read on a plate reader at 562nm.

Secondary measurements

were made with a Beckman coulter spectrophotometer set at 280nm wavelength.

2.6. Western Blot
Preliminary western blot studies were performed on a subset of plasma samples.
Precision plus protein standards (BioRad) were used as molecular weight standard
markers. Total human CNS protein (10 µg) was resolved on 4-12% gradient sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels (Novex, Life
Technologies, USA) and transferred to Immobilon-P membrane (Millipore). Membranes
were blocked overnight at 4°C in a Tris-buffered saline solution containing 1% Tween-20
(TBST), 5% bovine serum albumin (BSA) and 1%milk. Blots were incubated for one hour at
room temperature in primary antibody (human plasma (1:1000) or rabbit anti-GFAP
(1:6000) or rabbit anti-CRMP2 (1:1000)) that was diluted in a 5%BSA, 1%milk solution
(1:6000), washed with TBST, incubated for one hour at room temperature in secondary
antibody (anti-human or anti-rabbit alkaline phosphatase antibody 1:20,000 (Vector) as
appropriate in TBST containing 2%BSA and 1%milk), and again washed in TBST.
Membranes were developed with CDP-Star Reagent for alkaline phosphatase (BioLabs,
Ipswich, MA).
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Membranes were tested with and without primary antibody to distinguish between
the primary and secondary antibodies immunoreactivity. Plasma samples from subjects
that were determined to be positive or negative on the initial western blot screening were
re-screened to confirm immunoreactivity patterns using both CNS homogenate and purified
human recombinant GFAP (GFAP, OriGene TP304548) or purified human recombinant
CRMP2 (CRMP2, OriGene TP309080).

A custom-made anti-GFAP antibody or a

commercial anti-CRMP2 antibody was used as a positive control.

2.7. 2-Dimensional gel Electrophoresis
The first sets of 2-D gels were performed with Immobiline DryStrip gels, pH 311(immobilized pH gradient, IPG) (GE Healthcare Life Sciences, Pittsburgh, PA). For the
first dimension of the gel the IPG gels were rehydrated overnight. Enough CNS protein
sample was prepared for 135 µl per IPG gel. This consisted of 50µl of 4µg/ul (200µg) CNS
homogenate, 80µl Destreak buffer (GE Healthcare Life Sciences; containing urea,
thiorurea, CHAPS and Destreak reagent), and 1.3µl (1%) ampholytes. Each of 4 lanes of
the gel hydration chamber was loaded with 125µl of CNS protein in buffer. The IPG strip
was carefully placed on top of the sample assuring to keep the sample under the strip and
avoid trapping any air. About 3ml of mineral oil cover fluid was applied on top of the IPG
and assuring to place cover fluid at each end of the IPG to keep the sample under the gel.
Then the IPG gels and samples were covered and allowed to rehydrate at room
temperature overnight (Figure 2A).
The IPG gels were rinsed with deionized water and placed in the IEF chambers and
covered with oil, again allowing no air bubbles. The IEF chambers containing the IPG gels
were positioned so that the positive end (acidic) of the IPG strip was placed toward the
anodic electrode (+) and the negative end of the strip was placed toward the cathodic
electrode (-) (Figure 2B). The top was placed on the Ettan IPGphor II machine and a step
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gradient step protocol was run (1: 300v for 1hr, 300vhr at 15°C; 2: 1000v for 0:46hr, 500vhr;
3: 1000v for 0:30 hr, 500vhr; 4: 5000v for 1 hr; 5: 500 v for 1 hr; 6 100v for 11 hr, 1100vhr)
(Figure 2C). Starting with a low voltage reduces protein aggregation. During the isoelectric
focusing the blue dye migrates toward the anode, Figure 2D shows the dye has cleared.
Once the step gradient protocol was completed, the IPG strips were rinsed briefly in
deionized water and placed in 15ml conical tubes containing equilibration buffer (6M urea,
30% glycerol, 2%SDS, 1M Tris(pH6.8), 65mM DTT, and bromophenol blue as a tracking
dye) with the first tube including DTT reagent (0.14g/14ml) as a reducing agent for 30
minutes on a rocker followed by a second tube with lodoacetamide 2.5% (0.35g/14ml
equilibration buffer) to fix and equilibrate the sample (30 min on a rocker). Following this the
IPG gel was placed in the sample well on an 8% acrylamide gel (with the positive end/low
pI proteins on the side near the molecular weight markers). The second dimension
separation was performed with NuPAGE MES SDS running buffer and MES SDS (Figure
2E).
Two gels were placed in GelCode Blue for 1-8 hours then stored in 10% acetic acid.
Two gels were transferred to Immobilon-P membranes using NuPage transfer buffer with
15% methanol. Transfer was started at 30V then run for 90 minutes at 150mAmps. After
transfer membranes were blocked with 5% BSA and 1% milk for 12 hours on a rocker.
Membranes were then incubated with purified IgG from Time 1 (T1) or Time 2 (T2) plasma
in 5%BSA, 1% milk (1:500) for 3 hours. After rinsing in TBST (5 times), membranes were
incubated for 1hr in alkaline phosphatase secondary antibody in 2% BSA, 1% milk
(1:20,000). Membranes were rinsed again and placed in CDP-Star reagent buffer and
developed. The film was marked to assure proper alignment of the membrane-generated
spots with spots on the GelCode blue stained gel. New spots found in T2 were identified
and extracted from the corresponding gel for protein identification.
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Figure 2. 2-Dimensional Gel Electrophoresis
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2.8. Large Scale 2-Dimension Gel Electrophoresis
Large scale 2-D gels (20 x 22 cm) were used in order to spread out immunoreactive
spots and improve the precision of spot selection for protein identification using liquid
chromatography-mass spectrometry (LC-MS/MS). Large scale 2-D gels were prepared in
duplicate, one for Coomassie staining and one for western analysis according to a protocol
provided by Kendrick Laboratories (Madison, WI). [129, 130] Brain homogenate containing
phosphatase and protease inhibitors and SDS boiling buffer was treated with Omnicleave
and heated in a boiling water bath for 5 minutes. Protein concentration was ascertained
using the BCA Assay. Two-dimensional electrophoresis was performed using the carrier
ampholine method of isoelectric focusing. [129, 130] Brain sample (250µg) was loaded on
the first dimension gel. Each sample included an internal standard (tropomyosin (33,000))
and molecular weight markers (myosin (220,000), phosphorylase A (94,000), catalase
(60,000), actin (43,000), carbonic anhydrase (29,000), and lysozyme (14,000) (Sigma
Chemical Co., St. Louis, MO and EMD Millipore, Billerica, MA) as reference points for
orientation for later spot identification on the Coomassie stained 10% acrylamide gels
(second dimension gel). SDS second dimension gel electrophoresis was carried out for 5
hours at 25 mA/gel. Duplicate gels were then transferred onto PVDF membranes using the
same molecular marker proteins as reference points.
To identify cross-reacting self-antigens, sections from two Coomassie-stained sister
2-D membranes between approximately 30-75 kDa were cut and imaged. Then the
membranes were blocked, and probed with T1 or T2 plasma from samples found to
produce new immunoreactivity using T2 plasma on screening western blots. Concentrating
on the 30-75 kDa section of the 2-D membrane allowed conservation of precious plasma
sample. Protein spots on the 2-D T2 membrane with new or enhanced immunoreactivity
were identified. The scanned membrane images, tropomyosin marker and standards were
used as guides, and calipers were used to measure the precise locations of areas of
32

enhanced T2 membrane immunoreactivity. Clear transparency film was placed on top of
the membrane and the Coomassie-stained companion gel. The spots were marked on the
membrane transparency and this was matched to the gel and identified spots were circled
and numbered. Prior to excising spots, the locations were validated with the caliper
measurements. A photograph was taken of the numbered spots. The gel was wiped with
100% methanol and the spots were carefully cut out around the edges using a sharp, fresh
scalpel. Samples were speared with the tip of the scalpel and placed in sterile Eppendorph
tubes and capped immediately. Next 200µl of ultrapure water per spot was added to the
Eppendorph tubes. This was allowed to sit for 20 minutes prior to vortexing. The vortexing
removed the plastic film from the gel. The water was aspirated and the gel was moved to a
fresh Eppendorph tube labeled with the spot number. These spots were sent for LC-MS/MS
identification.

2.9. LC-MS/MS and protein identification
LC-MS/MS was performed by the Darie Laboratory at Clarkson University according
to published protocols.[131, 132] In brief, gel spots were washed rehydrated and trypsin
digested. The peptide mixture was analyzed by reversed phase liquid chromatography
(LC) and MS (LC-MS/MS) using a NanoAcuity UPLC (Micromass/Waters, Milford, MA)
coupled to a Q-TOF Ultima API MS (Micromass/Waters, Milford, MA), as previously
described.[131-135] A Mascot and PLGS database search provided a list of proteins for
each gel spot. The MS/MS spectra for the proteins identified by either one peptide or a
Mascot score lower than 25 were verified to eliminate false positives.

2.10. Statistical analysis
Statistical analysis was performed using SigmaPlot 11.0 (Systat Software, Inc.).
Descriptive data for subject groups was summarized as means and standard deviations
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(SD). Data was tested for normality using the Kolmogoroff-Smirnov test. For data that did
not pass the normality test, the Mann-Whitney Rank-Sum Test was used and the data are
presented as medians ± SE.

Kruskal-Wallis One Way Repeated Measures ANOVA

followed by Dunn’s Method for multiple comparisons was used when comparing the three
time points for acute SCI data. Spearman Rank Order Correlation was used to assess for
correlation between the continuous non-parametric GFAPab immunoreactivity or CRMP2ab
immunoreactivity and plasma complement C3 and C5 levels.

Two Way Repeated

Measures ANOVA followed by Holm-Sidak method for all pairwise multiple comparison was
used for comparing the C3 and C5 levels over time by pain group. Chi-square test was
performed to determine the relationship between the presence of multiple autoantibodies
and the development of neuropathic pain. Multiple logistic regression was performed to
assess the relationship between the presence of multiple autoantibodies and neuropathic
pain while controlling for other variables. Significance was defined as p < 0.05.

2.11. Method to Screen for autoantibody detection
Figure 3. Flow chart of methods for autoantibody detection

A. Patient samples used for autoantibody screening.
Patients were enrolled prospectively and classified according to their level of injury
and presence or absence of neuropathic pain (pain group).

The first autoantibody

screening experiments (Figure 3) performed were on the first consecutive 18 acute SCI
subjects enrolled to determine whether new immunoreactivity could be identified
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subsequent to SCI (Table 4). It is not possible to collect patient spinal cord tissue, nor is it
possible to test pre-injury samples from human SCI subjects to establish a baseline.
Therefore, a baseline sample <48 hours following injury (T1) served as the comparator to a
sample obtained 8-30 days post-injury (T2). Demographics on these acute SCI subjects
are presented in Table 4.

Subjects were primarily male (94%) with an average age of

38.1±14.6 years, 78% had complete or sensory incomplete injury (ISNCSCI A or B) and
78% were cervical neurological level injuries.

35

Table 4. Demographics of Subjects Used in Screening Studies.
Subject No. Age

Gender

Mechanism of Injury

ISNCSCI

Neurological
Level

(n=18)

of

Injury
1

61

Male

Bicycle

A

C4

2

37

Male

Motor vehicle collision

A

T3

3

37

Male

Fall

C

T12

4

26

Male

Fall

C

C5

5

20

Male

Motor vehicle collision

A

T6

6

36

Female

Motor vehicle collision

A

C4

7

18

Male

Motor vehicle collision

A

C7

8

57

Male

Motor vehicle collision

A

C5

9

69

Male

Fall

C

C5

10

39

Male

Bicycle

A

C4

11

26

Male

Diving

A

C6

12

21

Male

Motor vehicle collision

B

T9

13

30

Male

Motor vehicle collision

A

C5

14

52

Male

Assault

A

C4

15

35

Male

Car fell on his neck

C

C2

16

48

Male

Motor vehicle collision

A

C3

17

30

Male

Motor vehicle collision

B

C5

18

44

Male

Motor vehicle collision

A

C4
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B. Western blots for autoantibody screening
Western blots for autoantibody screening were performed as described in Chapter
2.7. Total CNS protein homogenate (10 µg) was separated on 4-12% SDS-PAGE gels and
transferred to Immobilon-P membranes. Western blots were performed on samples from
18 subjects at T1 and T2 to identify new immunoreactivity at T2 that was not present in T1.
These results of these western blots were dichotomized as positive or negative for new
immunoreactivity based on visual inspection. Additionally, similarities in molecular weight
of new immunoreactive bands between different patients’ T2 plasma samples were
assessed. A pattern of new immunoreactive bands ranging in size between 35-50kDa was
found in 4/18 (22%) subjects (Figure 4).[136]
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Figure 4. Representative western blot probed with human SCI patients’ plasma obtained at
T1 and T2.

Figure 4. Representative western blot probed with human SCI patients’ plasma
obtained at T1 and T2. The protein source for the gel was human cadaver
CNS homogenate. To reduce IgG contribution from the donor cadaver, the
cadaver was perfused with PBS prior to tissue extraction. A) a subject without
change in immunoreactivity between T1 and T2, B) a subject with increased
immunoreactivity between 35-50kDa at T2 compared to T1, and C)
immunoreactive

patterns

resulting

from

IgG

present

in

the

cadaver

homogenate, present when no primary was used. Bands at 50 and 25kDa are
heavy chain (hc) and light chain (lc) immunoglobulin G (IgG).

The new

immunoreactivity between 35-50kDa was present in 4 of 18 subjects tested.
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2.12 Method to identify antigens for autoantibodies

Figure 5. Flow diagram of experiments conducted to identify target antigens

Multiple techniques were tried to isolate the protein antigen.

For instance, IgG

purification was performed and affinity columns were created using recombinant protein A
to covalently crosslink the antibody in the plasma sample.

CNS homogenate was

incubated in the column and glycine elution was performed (Appendix). The amount of
antigen eluted from the column was found to be insufficient and, therefore, a new approach,
2-D gel electrophoresis was tested (Figure 5).

A. 2-D gels electrophoresis to separate human cadaver CNS protein
2-D gel electrophoresis as described in section 2.7 was used to separate human
cadaver CNS protein homogenate by isoelectric focusing and molecular weight. 2-D gels
were run in duplicate, one for each western blotting and Coomassie staining. Membranes
from the 2-D gels were probed with T1 or T2 SCI subject plasma known positive for new
immunoreactivity at T2. This was repeated using 3 different cadaver donors and two
different SCI subjects’ plasma. New or enhanced immunoreactivity was found at T2 in the
area between 35-70kDa. (Figure 6).

39

Figure 6. 2-D Gel with human CNS protein and membranes probed with SCI patients’
plasma

Figure 6. 2-D gel electrophoresis was used to separate human cadaver CNS homogenate by
isoelectric point (pI) and molecular weight. A) GelCode Blue stained gel showing spots which
are proteins that have been separated by pI and molecular weight. B and C) Membranes
derived from a corresponding 2-D gels; B was probed with T1 SCI patient plasma, C was
probed with T2 SCI patient plasma.

This SCI subject was known to be positive for new

immunoreactivity in the 37-50kDa range at T2.

New immunoreactivity can be seen in

membrane C (arrows).
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B. Excision of protein spots from 2-D gels
Protein spots of interest were identified using 2-D gels and western blot analysis
and excised as described in Methods 2.8. Large 2-D gels and corresponding membranes
were prepared in order to further separate the spots. Numerous membranes were probed
with two SCI patients’ T1 and T2 plasma. Areas of enhanced immunoreactivity at T2 were
identified.

Spots showing new immunoreactivity were carefully excised from the

corresponding Coomassie-stained 2-D gels and prepared for analysis by LC-MS/MS. An
example of membranes from a SCI subject’s T1 and T2 plasma and locations of spots
excised from the Coomassie-stained 2-D gel is shown in Figure 7.
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Figure 7. Large scale 2-D membranes and Coomassie stained gel showing spots
selected for LC-MS/MS.

Figure 7. Large scale 2-D membranes and Coomassie stained gel showing spots selected
for LC-MS/MS.
2-D gel membranes probed with T1 (A) and T2 (B) patient plasma showing enhanced
immunoreactivity at T2 compared to T1 from one of the four patients that previously
demonstrated increased immunoreactivity at T2 on 1-D gel membranes. Spots circled in
blue were identified for sequencing. They were located and cut out of the corresponding
Coomassie stained gel (C) and sent for identification by LC-MS/MS.

Glial fibrillary acidic

protein (GFAP) and collapsin response mediator protein 2 (CRMP2) were the predominant
proteins identified.
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C. LC-MS/MS protein identification
Excised proteins were subjected to LC-MS/MS and identified as described in
Chapter 2.9.
Dihydropyrimidinase-related protein 2 isoform 2 also known as collapsin response
mediator protein 2 (CRMP2) and glial fibrillary acidic protein (GFAP) and were the most
commonly identified proteins on the spots analyzed. CRMP2 was found in 11 spots and
GFAP was found in 7 spots when probed with different SCI patients’ plasma. The mass
spectrometry results for these proteins are presented in Table 5. The Mascot score
provided in Table 5 column three is the calculated probability (P) that the peptide match
between the experimental data and the database sequence is a random event (reported as
-10Log(P)). Peptides found above a pre-defined significance threshold are separated from
random scores. Generally, a higher Mascot Score is a higher probability of a correct match;
the score is separated out from the distribution of random scores indicating the match is not
a random event. All of the reported identified peptides have matches above the significance
threshold. As noted in section 2.9, Mascot scores lower than 25 were verified to eliminate
false positives. Of 22 spots evaluated there were 886 unique peptides mapped; 490/886
(55%) and 175/886 (19.8%) showed peptides that mapped to CRMP2 or GFAP
respectively. The remaining peptides may have resulted from contamination of nearby
proteins or they could be additional candidates. For example, a minority of peptides that
mapped to β-actin were present in two spots. However, when the blot was re-probed with
antibodies specific to β-actin, the immunoreactive signal did not co-localize with the location
of these spots, but rather an abundant adjacent spot. Multiple GFAP isoforms and their
post-translational modifications and have been shown in a staircase-like pattern in brain
tissue similar to what is found on the 2-D gels.[126, 137] CRMP2 protein and posttranslational modifications have also been seen with multiple spots in other studies as
CRMP2 is a highly phosphorylated protein.[138]
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Table 5. LC-MS/MS Findings
Number of

Protein Identified

Ranges

Range of

NCBI Accession

Spots

of

Number of

Number (gi

identified

Mascot

unique

number GenInfo

Scores

peptides

Identifier)

found per spot
11

dihydropyrimidinase-related

50 - 1005

9-109

giǀ4503377

142-1362

8-41

giǀ4503979

protein 2 isoform 2
[Homo sapiens]

7

glial fibrillary acidic protein
isoform 1 [Homo sapiens]
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Chapter 3.

Human SCI increases autoantibodies to

CRMP2
3.1. Introduction
A. Collapsin Response Mediator Protein 2 (CRMP2)
The cytosolic protein collapsin response mediator protein 2 (CRMP2) is also known
as dihydropyrimidinase-related protein 2 (DPYSL2, DRP-2) or turned-on-after-division-64
(TOAD-64).[139] CRMP2 is a member of the CRMP family of phosphoproteins. All of the
CRMPs (1, 2, 3, 4 and 5) are highly expressed in development with CRMP2 being the most
abundant CRMP at maturity.[139] In adults CRMP2 is expressed in neurons and
oligodendrocytes in the spinal cord and brain, and it has also been found in monocytes and
lymphocytes.[138, 140] CRMP2 has multiple known binding partners with which it affects
neurite growth, polarity, guidance, neurotransmitter release and calcium balance.[139]
CRMP2 activity is regulated through kinase-induced phosphorylation.

CRMP2’s

phosphorylation by cyclin-dependent kinase 5 (Cdk5) and glycogen synthase kinase-3β
(GSK3β) is necessary for the semaphorin 3A (sema3A)-induced growth cone collapse
which operates through microtubule reorganization or destabilization.[141, 142]
Along with sema3A, CRMP2 participates in axon guidance exerting an inhibitor role.
Sema3A is an axonal growth inhibitor which is expressed in fibroblasts and glia in the glial
scar 1 day to 4 weeks after SCI.[143] Kaneko et al. used a specific sema3A inhibitor
derived from fungus (SM-216289) in spinally transected rats to determine whether
neutralizing sema3A permits axon regrowth after SCI. SM-216289 inhibits growth cone
collapse and supports neurite lengthening.[143] The sema3A inhibitor was delivered to
rats via an osmotic mini-pump for 4 weeks after transection. More axonal regeneration
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within the lesion site in the sema3A inhibitor treated rats was observed compared to control
rats; some of these regenerated axons were from Schwann cells (PNS) that had migrated.
Calcitonin gene related peptide (CGRP)-positive fibers were increased in the sema3A
inhibited group compared to vehicle control group which was interpreted as sprouting of
unmyelinated C fibers which are associated with pain. However, no allodynia was reported
in these rats.[143] The effect of sema3A inhibition resulted in sprouting.
A separate study utilized a CRMP2-specific binding drug, Lanthionine ketamine
(100mg/kg/d IP for 4 weeks) in a thoracic 7 level SCI incomplete transection mouse model.
Fibrous scar tissue was measured by immunohistochemistry of Collagen IV fibrous tissue
within the glial scar and axonal sprouting was detected using 5-HT. Lanthionine ketamine
treated SCI mice had smaller areas of fibrous scar tissue and more axonal sprouting in the
serotoninergic raphespinal tract than vehicle treated SCI mice.[144] The intent of both the
sema3A inhibitor study and the Lanthionine ketamine study was to promote axonal
regeneration through the glial scar; however CRMP2 and sema3A’s effect glial scar
formation, axon extension and axon guidance was also demonstrated. The glial scar is
thought to be important for containing the injury site acutely after SCI and protecting intact
tissue from damage. (Please see section 4.1.A for additional discussion on the glial scar.)
CRMP2 promotes neurite growth and modification of cell structure through
interactions with tubulin, actin and neurofilaments.[139, 145]

CRMP2 expression was co-

localized with cytoskeletal protein βIII-tubulin in the white matter and marginal layer of the
spinal cord in a study of developing chick spinal cords demonstrating CRMP2’s
involvement in axon elongation and cytoskeletal structure modification.[141] The
expression patterns of CRMP2 on transverse sections of chick spinal cords were
compared at developmental stages permissive for regeneration (E11) and non-permissive
for regeneration (E15) in SCI crush injured versus sham operated chick spinal cords. After
injury there was a change in CRMP2 expression from white matter to gray matter, but there
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was not a difference in level of CRMP2 protein expression.[141] The CRMP2 redistribution
demonstrated CRMP2 movement from axons to the cell body as a response to injury.
Cell culture studies of human T cells identified CRMP2 in T cells and determined
that CRMP2 is involved with T cell migration and conformational changes.[140] In order for
T cells to migrate they must first become polarized. During T cell polarization CRMP2
relocates to the trailing edge (uropod) of T cells with vimentin (an intermediate filament
protein) where it is involved in motility through adhesive functions and cytoskeletal
rearrangement.[140] Semaphorins are involved in lymphocyte migration by steering and
facilitating or impeding cell motility.[140] CRMP2 is downstream of sema3A and transduces
sema3A guidance signals in addition to CRMP2’s participation in cell migration.[140]
CRMP2 presence in the uropod depends on the activated status of the T cell. The
presence of CRMP2 is important in directing T cells to the injury site. For example, blood
from patients who were infected with retrovirus HTLV-1 associated with neuroinflammation
had higher CRMP2 levels in activated T cells compared to healthy donor blood or HTLV-1
infected asymptomatic carriers.[140] Flow cytometry analysis of the HTLV-1 patients’
peripheral blood mononuclear cells (PBMC) identified CRMP2 in CD4+ and CD8+ T cells
and CD14+ monocytes/macrophages.[140]
CRMP2 phosphorylation is increased after SCI and increased phosphorylation of
CRMP2 has been associated with poorer outcome.[141, 146] Chondroitin sulfate
proteoglycans (CSPG) are also increased after SCI and CSPG inhibits axonal growth
through GSK3β activation.[147]

Inhibition of CRMP2 phosphorylation reduces CSPG-

induced inhibition of axonal growth, improves microtubule stabilization and increases
sensitivity to brain derived neurotrophic factor (BDNF).[146] BDNF is supportive of axonal
growth.

Nagai et al., using a near-complete dorsal transection SCI mouse model,

observed an increase in pCRMP2T509 (CRMP2 phosphorylation site of GSK3β) after SCI
in CRMP2+/+ mice, but CRMP2 protein expression had not changed. Phosphorylation at
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T509 was inhibited in CRMP2KI/KI mice. The SCI CRMP2KI/KI mice had better locomotor
recovery, regained nociceptive function and increased growth-associated protein 43
(GAP43) protein levels at the lesion site compared to CRMP2+/+ mice related to the
CRMP2 phosphorylation inhibition provided by the knock-in model.[146]

Dorsal horn

CGRP-positive (nociceptive) and 5-HT-positive (locomotor circuitry) fibers were present at
an increased density in CRMP2KI/KI mice and the inhibition of the phosphorylation of
CRMP2 in these mice also resulted in less immunoreactivity to GFAP (suggesting a
reduced inflammatory response) and a more compact glial scar.[146] These studies
illustrate that CRMP2 and its phosphorylation impacts axon sprouting, the glial scar and
inflammatory responses[146].

B. CRMP2 and neuropathic pain
Aberrant nociceptive fiber sprouting could lead to neuropathic pain.[148-150]
Nerve growth factor (NGF) enhances nociception and induces axonal elongation and
sprouting.[145, 151] A study that used dissociated sensory neurons from chick dorsal root
ganglia demonstrated that neutralizing CRMP2 potentiated NGF-induced neurite
outgrowth.[145] Investigators neutralized CRMP2 activity with anti-CRMP2, or with a
dominant-negative form of CRMP2, in the presence of NGF which resulted in more DRG
with neurites and lengthened neurites.[145] Additionally, CRMP2 antibodies triturated into
DRG neurons blocked sema3A-induced growth cone collapse suggesting that CRMP2 is
involved as a negative regulator of NGF-induced neurite growth.[145] Through inhibition of
CRMP2, sprouting was induced; CRMP2 functionally inhibits sprouting.
NGF mRNA expression in adult rat spinal cord was shown to be elevated up to 4
days after injury indicating conditions for NGF-induced neurite growth after SCI.[152]
CGRP immunoreactivity (nociceptive) is shown to increase in deeper lamina III and IV in
spinally hemi-sectioned rats; however the administration of anti-NGF in this model reduced
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CGRP expression in lamina I and II and prevented projection of CGRP into lamina III and
IV suggesting anti-NGF inhibited sprouting of primary pain afferents.[151]
These studies support the possibility that after SCI an autoantibody to CRMP2 could
contribute to blocking sema3A-induced growth cone collapse and/or increase the number
of cells with neurites and the length of neurites in the DRG. These neurites, that would
normally extend only to lamina I and II, in the presence of autoantibody to CRMP2 may
project into deeper lamina. This sprouting of sensory neurons into deeper lamina related to
the presence of an autoantibody to CRMP2 could lead to neuropathic pain.[150]
CRMP2 is a regulator of N-type voltage-gated calcium channel activity. The binding
of CRMP2 to N-type voltage-gated calcium channels in a Cdk5-phosphorylation dependent
manner amplifies calcium currents and increases neurotransmitter release in sensory
neurons.[146, 153]

Inhibition of this interaction or inhibition of the phosphorylation of

CRMP2 reduces transmission of pain signals, possibly because of CRMP2’s regulation of
voltage-gated channels.[154] However, it is possible that an autoantibody to CRMP2 could
interfere with the CRMP2-N-type voltage gated calcium channel regulation balance. The
abnormal calcium influx into N-type voltage-gated calcium channels has been suggested to
be related to neuronal excitability and pain.[154]
The hypothesis is that an autoantibody to CRMP2 contributes to the development of
neuropathic pain. The potential for a relationship between the development of neuropathic
pain and the presence of CRMP2ab in SCI patient plasma may result in clinically important
findings. Therefore, correlative experiments with human plasma samples were performed
to validate findings of CRMP2 as a potential antigen for the production of autoantibodies
involved in the development of neuropathic pain.

3.2. Methods.
A. Fluorescent western blots on 2-D gel membranes
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Fluorescent western blotting was performed to determine whether there are
overlapping areas of immunoreactivity produced by T2 SCI patient plasma and a
commercial anti-CRMP2 on 2-D gel membranes. A section of a 2-D gel membrane at the
same molecular weight and isoelectric point range that was used to identify CRMP2 as a
potential antigen was selected. This membrane was probed with T2 SCI plasma and a
commercial anti-CRMP2 antibody. Some overlapping immunoreactivity between the patient
plasma and anti-CRMP2 was expected if CRMP2 is a valid antigen.
The membrane was cut and scanned, wet with methanol, destained and blocked (in
filtered PBST with 5%BSA, 1% milk) for 2 hours. The membrane was incubated overnight
on a rocker at 4°C in plasma T2 primary (1:500 in filtered PBST with 5% BSA, 1% milk).
The membrane was then incubated in anti-CRMP2 raised in rabbit (1:1000, in filtered PBST
with 5%BSA, 1% milk) for 8 hours. After washing in PBST the membrane was incubated
with Alexa Fluor 488 (green) goat-anti-human IgG secondary (1:500) and Alexa Fluor 568
(red) goat-anti-rabbit IgG secondary (1:500) for 1 hour. This was followed by washing. To
read the fluorescent signal, the membrane was placed protein side down on the Typhoon
Trio scanner. The emission settings used for 50um scans were 5265P Fluor Cy Alexa
Fluor, 488, PMT 375 and 610 BP30 green, 532, deep purple spyro ruby, PMT 375.

B. SCI plasma immunoreactivity to purified recombinant CRMP2
Western blots were performed as described in Chapter 2.7 to validate plasma
immunoreactivity to CRMP2. SCI patient plasma samples known to be positive at T2 for
the presence of autoantibodies found in the initial screening western blots were used to
probe purified recombinant protein of human CRMP2. In this experiment 8% acrylamide
gels were used in order to increase the separation of proteins between 37-75kDa. Purified
recombinant CRMP2 (0.25µg/well) was used as the antigen that was probed with patient T2
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plasma (1:500) or anti-CRMP2 (1:1000) followed by alkaline phosphatase secondary
(1:50,000) and developed with West Pico.

C. CRMP2 immunodepletion of brain homogenate.
Figure 8. Flow chart of Immunodepletion of brain homogenate.

The goal of the immunodepletion was to have CRMP2-poor brain homogenate to
use for western blot (Figure 8). Protein A agarose resin (Pierce) was used to remove the
CRMP2 from brain tissue homogenate. The IgG from the brain tissue was depleted first to
assure that donor brain tissue IgG was not contributing to immunoreactivity. 50µl of Protein
A agarose resin was centrifuged, washed with 1ml PBST and centrifuged again to remove
the 1ml wash. Brain supernatant (0.7µg/ul protein per microBCA) was added to 25µl resin
beads. A second aliquot of 25µl resin beads was combined with 25µl anti-CRMP2 plus
261µl of 2%BSA in PBST to bring samples to an equivalent volume. Both were allowed to
incubate overnight in the cold room on an agitator. After incubation these samples were
centrifuged for 5 min at 500Xg, and each of the supernatants were divided in half. The
CRMP2 beads were washed twice in 1ml PBST. Half of the IgG-depleted brain supernatant
was combined with the anti-CRMP2 beads to deplete the CRMP2 from this sample. The
supernatant and beads were allowed to incubate for 8 hours. Dot blots with anti-CRMP2
were used to confirm depletion of CRMP2 from the sample.
The IgG-depleted brain or the CRMP2-depleted brain supernatants (5µg
protein/well) were run on an 8% acrylamide gel and proteins were transferred to an
immobilon-P membrane. The membrane was probed with patient T2 plasma (1:500) or
anti-CRMP2 (1:1000) followed by alkaline phosphatase secondary (1:50,000) and
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developed with West Pico.

These Western blots were run to determine whether the

immunoreactivity produced by patient plasma that was shown to be immunoreactive to
purified CRMP2 decreased when probing the CRMP2-depleted brain sample.

D. Capillary electrophoresis–immunoassay
After identifying patient plasma samples containing anti-CRMP2 immunoreactivity
using western blots, the specificity of immunoreactivity was verified using a commercial
anti-CRMP2 antibody and purified recombinant human CRMP2 protein with a capillaryelectrophoresis immunoassay.

All subject samples were then tested on this capillary-

electrophoresis immunoassay. Purified recombinant protein CRMP2 (36ng/µl) was
denatured with SDS-containing buffers and florescent standards and subsequently loaded
into capillaries for separation by size. Ultraviolet light was used to immobilize the proteins
to the capillary wall where they were probed with plasma primary (1:100) and anti-human
HRP secondary 1:500 (Vector). Separation was run for 25 minutes at 375 volts, antibody
diluent incubation time was 5 minutes, primary antibody incubation time was 30 minutes,
secondary antibody incubation time was 30 minutes and detection used multi-image
analysis of 5 exposures (1, 2, 5, 15 and 30 seconds). Chemiluminescence (produced by
luminol and peroxide) was acquired by a charge-coupled device camera and the image was
measured and peaks were detected by the system software (Compass for SW,
ProteinSimple, V3.0.9). System parameters were set with a peak threshold of 10, width of 9
and a Gaussian fit for area calculation. Each assay included positive control capillaries of
the commercial anti-CRMP2 antibody (1:1000) and an anti-rabbit secondary, a negative
control of no primary antibody (antibody diluent only), and a known positive human plasma
sample (identified through 1-D and 2-D gel testing). All time points for an individual subject
were assayed by capillary electrophoresis -immunoassay on the same capillary array to
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minimize between-assay variability for a subject. All immunoassays were performed on the
same instrument.
The area under the curve (AUC) and the signal to noise ratio (S/N) were calculated
with the assay software (Compass for SW, ProteinSimple, V3.0.9). Existence of a curve
was confirmed by visual inspection. The measurements of AUC, in arbitrary units, were
used for comparison between groups.

E. Determination of specificity of autoantibodies
To verify antigen-binding specificity, competition studies were performed on the
diluted plasma (1:100) samples that were analyzed for reactivity to CRMP2 protein using
the capillary electrophoresis-immunoassay. Plasma samples were incubated overnight at
4°C either with 360ng purified CRMP2 protein/10µl of plasma or a competing protein of a
similar molecular weight that contained the same tag (Myc-DDK) used for purification (glial
fibrillary acidic protein, GFAP or calreticulin, CALR) of an equimolar amount.
Immunoreactive signals to CRMP2 obtained with the pre-absorbed samples (CRMP2,
GFAP or CALR) were compared to immunoreactive samples from the plasma sample that
was not pre-absorbed. Anti-CRMP2-specific immunoreactivity should be diminished if there
is cross-reactivity with the CRMP2-pre-absorbed sample. Immunoreactivity from samples
deemed anti-CRMP2-specific had to have a decrease in AUC. Immunoreactivity that had a
similar decrease when pre-absorbed with GFAP and/or CALR was deemed non-specific.
The presence of plasma anti-CRMP2 (CRMP2ab) was considered positive if 1) the AUC
was above the level of background noise and 2) the AUC decreased greater than 30%
when pre-absorbed with the CRMP2 protein, but not the pre-absorbed competing
protein(s).
BLAST (National Center for Biotechnology Information, U.S. National Library of
Medicine) searches for homology between CRMP2 and GFAP or CALR were performed.
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The BLAST search for CRMP2 and GFAP resulted in 3 matches, one of which had 6
sequential amino acids. The BLAST search comparing peptide sequences for CRMP2 and
CALR identified two areas with overlapping peptide sequences, one had 8/20 the other
8/28 identical peptides, at most there were only 3 sequential amino acids.

F. Analysis of CRMP2ab levels by pain group
Patients were classified as positive or negative for neuropathic pain based on a
clinical diagnosis of neuropathic pain as describe in Section 2.3. Acute SCI subjects were
divided into those classified as positive for neuropathic pain within 6 months post-SCI
versus those who did not have evidence of neuropathic pain by that time. Chronic SCI
subjects were classified according to their pain status at the time of sampling.

A

comparison of the S-LANSS scores (as described in Chapter 2.3B) between pain groups
was performed as a corroboration of the clinical diagnosis of neuropathic pain. The MannWhitney Rank-Sum Test was used to determine whether there was a difference in the
levels of CRMP2ab at 16 ± 7 days in those with versus without neuropathic pain within 6
months of SCI.

3.3 Results
A. Fluorescent staining validates CRMP2 as a source of
immunoreactivity
Probing the membrane with T2 plasma followed by anti-CRMP2 utilizing anti-human
or anti-rabbit specific secondary antibody with fluorescent tags confirmed co-localization of
SCI plasma and CRMP2 immunoreactivity (Figure 9). For further confirmation, calipers
were used to make precise measurements of co-localized spot locations and spots from
corresponding gels were cut and sent for repeat LC-MS/MS identification. The repeat LC-
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MS/MS results confirmed the original CRMP2 findings. These findings implicate CRMP2 as
a potential antigenic target of an autoimmune response after SCI.
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Figure 9. CRMP2 Verification, Co-localization of Immunoreactivity.

Figure 9. CRMP2 Verification, Co-localization of immunoreactivity.
Coomassie stained membrane after transfer from a 2-D gel containing CNS proteins (A). The
membrane was probed with T2 SCI patient plasma known to be immunoreactive and Alexa
Fluor 488 (green) goat-anti-human IgG secondary (B).

The same membrane was also

probed with anti-CRMP2 (rabbit) and Alexa Fluor 568 (red) goat-anti-rabbit IgG secondary
(C). Arrows show co-localization of some of the fluorescent green and red spots (D).
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B. Western blotting confirms T2 SCI plasma immunoreactivity to
purified recombinant CRMP2.
Representative results are shown in Figure 10. The SCI plasma sample shown
below is immunoreactive to CRMP2 at T2. The commercial anti-CRMP2 positive control
developed a broad single band at the same molecular weight location. These results are
consistent with the findings from the LC-MS/MS showing SCI patient plasma
immunoreactivity to CRMP2.

Figure 10. Western blot showing patient plasma at T2 with banding pattern consistent with
positive immunoreactivity to CRMP2 protein.

Figure 10.

Western blot showing SCI patient plasma at T2 with banding pattern

consistent with positive immunoreactivity to CRMP2 protein. Lane 1 shows Patient T2
plasma probed against purified recombinant CRMP2 protein. Lane 2 is a commercial
anti-CRMP2 antibody.

These results are consistent with the LC-MS/MS results that

identified CRMP2 as a potential antigen.
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C.

Immunodepletion of brain tissue demonstrates a decrease in T2

plasma immunoreactivity at the molecular weight of CRMP2.
Immunoreactivity decreased in the CRMP2-depleted brain at the molecular weight
level of CRMP2 bands. Representative results are shown in Figure 11.

Figure 11. Decreased Immunoreactivity of T2 Patient Plasma on CRMP2-depeleted
brain sample.

Figure 11.

Decreased immunoreactivity of T2 patient plasma on CRMP2-

depleted brain sample.
Protein A agarose resin beads were used to deplete brain homogenate of IgG
and then further deplete the homogenate of CRMP2. Lane 1 shows
immunoreactivity of a T2 SCI patient sample against IgG-depleted brain. On
Lane 2 the same plasma was used to probe the brain sample that was depleted
of CRMP2.

The reduced immunoreactivity from patient plasma in Lane 2

suggests this patient plasma is immunopositive to CRMP2.
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D. Capillary electrophoresis immunoassay is effective at measuring the
SCI plasma for immunoreactivity to CRMP2
The previous experiments confirm that some SCI subjects produce immunoreactivity
to the CRMP2 antigen that was identified through 2-D electrophoresis and LC-MS/MS. In
order to estimate the percent of the acute SCI subjects who are positive for CRMP2ab
purified recombinant CRMP2 protein was used as the sample on a capillary electrophoresis
–immunoassay.

Increasing dilutions of plasma and amounts of protein were tested to

determine loading amounts. An illustration of the difference of immunoreactivity to CRMP2
from the same plasma sample at dilutions of 1:50 or 1:100 is shown in Figure 12. Plasma
dilutions of 1:100, and CRMP2 protein at 36 ng/µl were used for these studies.
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Figure 12. Example of assay for CRMP2 plasma dilutions and protein volume

Figure 12. Preliminary capillary electrophoresis immunoassays were performed to determine the
amount of protein and the dilution of plasma antibody to use for subsequent testing. The image on
the left shows immunoreactivity from one plasma sample of one patient that was diluted either
1:50 or 1:100 used to probe CRMP2 protein 36 or 72 ng/µl. The image on the right shows the
corresponding areas under the curve (AUC). Plasma dilutions of 1:100, and CRMP2 protein at 36
ng/µl was selected for subsequent studies.
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The level of immunoreactivity produced by acute SCI patient plasma in response to
CRMP2 protein was measured in serially collected plasma samples as the timing of
production of autoantibodies was expected to have some variability in different patients.
The 16 ± 7 day sample time point produced the peak immunoreactivity. Figure 13 shows
an image of the immunoreactivity on the capillary electrophoresis immunoassay of samples
at three time points from a SCI patient that was also immunopositive to CRMP2 on
acrylamide gels.
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Figure 13. Capillary electrophoresis immunoassay of patient plasma on CRMP2 protein.

A

Figure 13.
protein.

B

Capillary electrophoresis immunoassay of patient plasma on CRMP2

A) Immunoassay: Lanes 1-3 probed with patient plasma (1:100) at 3 time points on
36ng/µl of CRMP2. Lane 4 shows no immunoreactivity using no primary and antihuman HRP (1:500) secondary. The positive control commercial anti-CRMP2 (1:1000)
is in Lane 5. B) Corresponding graph of immunoreactivity of SCI plasma. The green
color identifies the area measured to calculate AUC of CRMP2ab.
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E. Specificity of Immunoreactivity
E.1 Subjects used in antigen-binding specificity and subsequent studies
Acute, chronic and healthy volunteers were evaluated to test for the presence of
CRMP2ab. A total of 138 subjects (20 healthy volunteers, 38 acute SCI and 80 chronic
SCI) were consented and enrolled for their participation in this study. The demographics of
these subjects are reported in Table 6. On average, the acute SCI patients were 1.2 days
post-injury, whereas the chronic SCI patients were 15 years from injury. The primary cause
of injury in the majority of SCI patients was motor vehicle accidents (MVA). The acute and
chronic SCI groups included primarily cervical injuries and over half of each SCI group was
ISNCSCI A or B impairment level (A: complete loss of function; or B: sensory, but no motor
function was preserved below the level of the injury).
Acute SCI subjects were divided into those classified as positive for neuropathic
pain within 6 months post-SCI versus those who did not have evidence of neuropathic pain
by that time. Chronic SCI subjects were classified according to their pain status at the time
of sampling. In both acute and chronic SCI groups, all subjects with an S-LANSS score of
greater than 12 had a clinical diagnosis of neuropathic pain. The chronic subjects with
neuropathic pain had a significantly higher S-LANSS score than those without neuropathic
pain (T=741, median 9 vs. 0, p<0.001), but there was no difference on the McGill pain
score.

S-LANSS scores were available for 18 acute SCI subjects at 6 months, when

combining these scores with the chronic subjects’ scores, the combined S-LANSS scores
were significantly different between those with a clinical diagnosis of neuropathic pain and
those without neuropathic pain (T=1091, median 9 vs. 0, p<0.001) corroborating the clinical
diagnoses of neuropathic pain (Figure 14). The affective descriptors (tiring-exhausting,
sickening, fearful, and punishing-cruel) on the McGill pain score were significantly higher for
the acute SCI patients with neuropathic pain compared to those without neuropathic pain
(mean 3.5 ± 3.2 vs 0.2 ± 0.4, p<0.04). Of the 38 acute SCI subjects, 23 (60.5%) were
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diagnosed as having neuropathic pain by the 6 month time point while 15 (39.5%) had no
evidence of neuropathic pain. Key demographics of the acute SCI subjects by pain group
are shown in Table 7.
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Table 6. Demographics of subjects used for capillary-immunoassay studies
ACUTE
SUBJECTS
(N=38)

SCI

CHRONIC
SCI
SUBJECTS (N=80)

HEALTHY
VOLUNTEERS (N=20)

GENDER, COUNT (PERCENT)
MALE

34 (89)

59 (74)

16 (80)

FEMALE

4 (11)

21 (26)

4 (20)

AGE, AVERAGE YRS(SD)

43.5 (17.7)

44.1 (14.0)

35 (13.2)

AGE, RANGE YEARS

18-82

19-76

20-62

WHITE

32 (84)

66 (82)

11 (55)

ASIAN

0 (0)

3 (4)

6 (30)

BLACK

5 (13)

11 (14)

3 (15)

OTHER

1 (3)

0 (0)

0 (0)

HISPANIC

6 (16)

19 (24)

0 (0)

NOT HISPANIC

32 (84)

61 (76)

20 (100)

RACE, COUNT (PERCENT)

ETHNICITY

MECHANISM OF INJURY, COUNT (PERCENT)

N/A

MVA

23 (60)

47 (59)

FALL

10 (26)

19 (24)

SPORTS-RELATED

4 (11)

10 (13)

ASSAULT

1 (3)

4 (5)

TIME POST-SCI AT ENROLLMENT
AVERAGE (SD)

N/A

1.2 DAYS

15.3 (12.3) YEARS

RANGE
LEVEL OF INJURY

0.1-2.7 DAYS

1- 41 YEARS

CERVICAL

31 (82)

47 (60)

THORACIC

6 (16)

22 (28)

LUMBAR

1 (2)

4 (5)

UNKNOWN

7 (9)

ISNCSCI Impairment Scale
A

23 (60)

28 (35)

B

3 (8)

21 (26)

C

8 (21)

11 (14)

D

4 (11)

12 (15)

N/A

8 (10)
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Figure 14. Box plot of S-LANSS Pain scores by pain group for Acute SCI
and Chronic SCI patients. Acute SCI patients were classified as having
neuropathic pain within 6 months of injury and chronic subjects were
classified based on their pain state at the time of the visit (on average 15
years post-injury).

Neuropathic pain classification was based on the

clinical diagnosis of neuropathic pain and the S-LANSS score reported by
patients supports the classification.[121] (T=1091, median 9 vs. 0,
p<0.001)
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Table 7. Demographics of acute SCI by pain group
Neuropathic Pain (n=23)

No Neuropathic

P*

Pain (n=15)
Age (years, median)

36

47

0.69

BMI

26.5

27.8

0.94

Male gender

19

15

0.14

Complete (ISNCSCI A)

14

9

1.0

Cervical Level Injury

15

14

0.06

(kg/m2, median)

*Mann-Whitney rank sum test for variables not normally distributed. Fisher’s exact test was used for
variables with small expected cell number. No significant results were found for any variables.

67

E.2 Specificity of Immunoreactivity to CRMP2
Specificity of immunoreactivity to CRMP2 was determined by pre-absorption of the
plasma with purified CRMP2 or a non-specific protein (i.e. GFAP or CALR) which contained
the same tag (Myc-DDK) used for purification.

Only samples with immunoreactivity that

was blocked by the pre-incubation with CRMP2, but not GFAP or CALR, were considered
positive for CRMP2ab (Figure 15). Samples that demonstrated reduced immunoreactivity
to both blocking (CRMP2) and competing (GFAP or CALR) proteins were considered
nonspecific and therefore not counted as CRMP2ab positive (Figure 16). Only those
samples that 1) had immunoreactivity above baseline, 2) decreased > 30% when preblocked with CRMP2 and 3) did not decrease when pre-absorbed with GFAP or CALR were
deemed as having specific immunoreactivity to CRMP2 and were classified as CRMP2ab
positive.
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Figure 15. SCI patient plasma immunoreactivity specific for CRMP2.

Figure 15. SCI patient plasma immunoreactivity specific
for CRMP2.

A) Image showing SCI plasma

immunoreactivity to CRMP2 (lane 1), plasma preblocked with CRMP2 (lane 2), plasma pre-blocked with
competing protein (GFAP) (lane 3), no primary showing
no immunoreactivity (lane 4), anti-CRMP2 positive
control (lane 5). Immunoreactivity from plasma is not
seen in lane 2 that was pre-blocked with CRMP2, but it
is present in the plasma that was pre-blocked with GFAP
showing the plasma antibody in this sample is specific
for CRMP2. B) AUC of plasma, pre-blocked plasma and
competed

plasma.

C)

Graphic

representation

immunoreactivity change with blocking.
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Figure 16. CRMP2 Blocking and Competing Studies – SCI patient non-specific for CRMP2.

Figure 16. CRMP2 Blocking and Competing Studies – SCI
patient non-specific for CRMP2. SCI plasma was incubated
overnight in standard block (1:100) or equimolar amounts of
CRMP2, GFAP or CALR protein. These samples were then
used to probe CRMP2 protein. A) Lane 1 shows plasma
immunoreactivity to CRMP2, Lane 2 the plasma was preblocked with CRMP2 and immunoreactivity was reduced as
expected. Lane 3 the plasma was pre-blocked with GFAP
and Lane 4 the plasma was pre-blocked with CALR. Preblocking with these competing proteins also reduced
immunoreactivity indicating this response is non-specific. B)
AUC of the immunoreactivity, C) Graphic representation of
immunoreactivity change with blocking.
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The Grubbs’ test was performed to determine whether any samples in either group
were outliers. One healthy volunteer was found to be a significnat outlier (Z=2.71, p<0.05)
and was removed from analysis. Results indicated 8/35 (23%) SCI subjects and 1/19
healthy controls (5%) were CRMP2ab positive. However, the difference in the median
levels of CRMP2ab was not significantly different between SCI subjects at the 16 ± 7 peak
time point and healthy controls (T=461.0, p=0.09). CRMP2ab was detected in chronic SCI
subjects, however because the peak acute timepoint did not reach significance the antigen
verification studies were halted.

F. No statistically significant difference in the levels of CRMP2ab at 16 ±
7 days in acute SCI patients who developed neuropathic pain versus those
who did not.
The results of the CRMP2 antigen verification and competition studies above
identified 8 of 35 (23%) subjects had immunoreactivity that was specific for CRMP2 protein
at 16 ± 7 days after SCI. (Three subjects with immunoreactivity did not block with CRMP2
and were omitted; the 6 day sample was used for the one subject who did not have a
sample at 16 ± 7 days.) There was no difference in median CRMP2ab levels of those with
and without neuropathic pain (T = 231.000, p = 0.08) (Figure 17). Sample size calculations
based on data from theses acute SCI subjects indicate that a total of 64 subjects would be
needed to detect a significant difference at an 80% power with an alpha of 0.05.
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Figure 17. CRMP2ab levels at 16 ± 7 days after SCI were not statistically
different between those who developed neuropathic pain (n=20) compared to
those who did not develop neuropathic pain (n=15) within 6 months after SCI
(T=231.000, p=0.08).
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3.4. Discussion
A. Key findings
Eight of thirty-five (23%) subjects were identified as CRMP2ab positive after SCI.
There was no difference in median CRMP2ab levels of those with and without neuropathic
pain (T = 231.000, p = 0.08). Although this did not reach significance, it could be due to
limited number of positive patients. Sample size calculations based on data from theses
acute SCI subjects indicate that a total of 64 subjects would be needed to detect a
significant difference at an 80% power with an alpha of 0.05.
B. Spots observed
Of the 22 spots sent for evaluation, 11 were positive for CRMP2. Of the spots
matched to CRMP2, the molecular weight and species were correct. Figure 8 above,
reveals spots that are likely different isoforms and post-translational modifications of
CRMP2. There are multiple isoforms of CRMP2 including 75kDa CRMP2A and 62-66kDa
CRMP2B variants that are commonly observed in adult CNS tissue.[139] One of the spots
showed 59% coverage and the coverage included peptides in the N (glutamine 8, Q8) and
C terminals (lysine 465, K465) supporting that it was identifying CRMP2, not homologous
parts of other isoforms. CRMP2 has been identified as a potential antigen causing human
plasma immunoreactivity previously on 2-D gels as a 62kDa protein with two
phosphorylated isoforms at 64kDa and 66kDa.[155] Additionally, 55kDa CRMP2 breakdown
products have been previously identified.[156] Spots that are more negatively charged
(more phosphorylated) migrate to the left/acidic side of the 2-D gel.[141] Cyclin-dependent
kinase 5 (CDK5) phosphorylates CRMP2.[157] In a chick SCI crush injury study CDK5 was
inhibited with roscovitine in explanted cells. Using βIII-tubulin staining neurite sprouting and
cell migration was detected, and in some cells there was an increase in phosphorylation at
S522 mediated by CDK5. Two known sites of phosphorylation of CRMP2 are at threonine-
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514 (70 and 78kDa) and serine-522 (62 and 70 kDa); phosphorylation at both residues was
shown at 70 and 78kDa in chick spinal cord.[141]
C. Mechanism(s) by how CRMP2 autoantibody may contribute to neuropathic
pain
CRMP2 autoantibody may contribute to neuropathic pain by fostering the sprouting
of pain fibers. Aberrant sprouting of afferent fibers occurs after SCI. Calcitonin gene
related peptide (CGFP) in the dorsal horn is a nociceptive neurotransmitter.[150] After SCI
neurite spouting measured by increased density of growth associated protein-43 (GAP-43)
co-localized with α-CGRP indicating nociceptive primary afferent sprouting in laminae
where these primary afferents are not normally found.[150] In human postmortem subjects
immunohistochemistry and immunocytochemistry for CGRP were performed on thoracic
spinal cord tissue comparing 4 chronic SCI spinal cords below the level of the lesion and 5
intact control spinal cords. Confirming rodent studies, CGRP-containing fibers were found
in both groups in lamina I and II, but in the human SCI tissue, fibers were denser and
extended into deeper laminas III-V, VII and X.[158] Previous experimental rat studies
demonstrated CGRP nociceptive sprouting was associated with hyperalgesia and
allodynia.[151]
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Chapter 4. Human SCI elicits an autoantibody response to
GFAP
4.1. Introduction
A. Astrocytes
Astrocytes are the most abundant of central nervous system (CNS) glial
cells.[159] Astrocytes provide structural support for neurons and facilitate the uptake of
neural transmitters and maintenance of the blood-spinal cord barrier (BSCB).

Astrocytes

also control the migration of immune-mediating leukocytes into and out of the injured spinal
cord.[160] Astrocytes can exert chemical signals that recruit leukocytes into the spinal
cord parenchyma (pro-inflammatory) or restrict their entry (anti-inflammatory effect).[160]
For instance, vascular endothelial growth factor A (VEGFa), derived from astrocytes,
induces permeability of the BSCB and entry of leukocytes.[161]
Astrocytes are intricately involved in the BSCB providing chemical support for
endothelial cells and maintaining the ion balance.[160] After trauma to the spinal cord,
astrocytes are activated by cytokines and growth factors (e.g., IL-1, IL-6, TGFα, TGF-1,
bFGF) becoming reactive.[160] Two types of reactive astrocytes have been identified, A1
and A2.

A1 astrocytes are generally considered neurotoxic generating a pathological

response whereas A2 astrocytes stimulate neuronal survival and healing of injured
tissue.[162] Reactive astrocytes surround the injured area creating a glial scar.
The glial scar is thought to be protective by sequestering the damaged area and
promoting cleanup of myelin and cellular debris, but the glial scar prevents axon
regeneration across the scar, inhibiting recovery.[163, 164] After SCI astrocytes
hypertrophy and form a mesh-like barrier around the lesion core.[165] Confining the
inflammatory cells within the glial scar protects intact cells from macrophage-induced
damage.[166] The reactive astrocytes forming the glial scar recruit inflammatory mediators
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(chemokines, cytokines, growth factors, prostaglandin, nitric oxide) and perform a barrier
function, restricting the spread of inflammation to uninjured tissue (Figure 18).[160]
Consistent with this, reactive astrocytes that were experimentally ablated near the injury
site by the antiviral ganciclovir in transgenic herpes simplex virus mouse stab and crush
injury models demonstrated markedly worse tissue damage, demyelination, increased
leukocyte infiltration and poorer motor function compared to control injured mice.[167, 168]
GFAP is essential for astrocytes’ glial scar formation.[169]
Astrocytes are involved with autoimmune pathology. For example, the disruption of
astrocyte functions by binding of complement and autoantibodies that bind to aquaporin 4
(AQP4) on astrocyte membranes is causal of neuromyelitis optica (NMO), a demyelinating
disease of the eye which leads to loss of vision.[160] The AQP4-autoantibodies result in
complement-mediated astrocyte damage, blood-brain barrier breakdown, increased
inflammation and enlarged tissue damage.[160] Furthermore, in NMO astrocyte-associated
damage of the optic nerve and spinal cord can cause pain.[170]
Gliopathy, defined as “the dysfunctional and maladaptive response of glial cells to
neural injury” is proposed to be the result of the sudden increase in extracellular glutamate
concentration resulting in excitotoxicity, sensitization of neurons and glia and includes
increase of pro-inflammatory cytokines and immune cell infiltration.[171] Gliopathy results
in ongoing inflammation and neuropathic pain.[171]
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Figure 18. Model of spinal cord injury showing reactive astrocytes creating a
glial scar.

Figure 18. Model of spinal cord injury showing reactive astrocytes creating a
glial scar.
A spinal cord injury causes damage to neurons resulting in dystrophic growth
cones, degenerating axons and cellular debris.
After trauma to the spinal cord, astrocytes are activated by cytokines and growth
factors becoming reactive astrocytes in response to the trauma.

Reactive

astrocytes surround the area of injury creating a glial scar. The glial scar is
protective by sequestering the damaged area and promoting clean up, but also
inhibits axons ability to regenerate across its inhospitable territory.[166] The
model shows activated astrocytes surrounding the injury site.
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B. The Role of GFAP
GFAP knock-out mouse models have shown reduced glial scar formation in GFAP
knock-out mice.[169, 172] This weakened glial scar may contribute to a persistently
permeable BSCB, or it may promote axonal growth across the lesion.[172]
DNA microarray analysis on rat spinal cord after SCI found upregulated genes
associated with inflammation and astrocyte activation in rats with SCI and chronic pain
compared to SCI rats without chronic pain.[25] GFAP mRNA and protein expression were
elevated in SCI and further increased (more than 2-fold) in SCI rats with chronic pain. The
increase in GFAP expression started as early as 4 hours after injury and persisted for 9
months in chronic pain SCI rats.

Activation of astrocytes and the accompanying pro-

inflammatory state is associated with chronic pain. The authors propose that persistent
astrocyte hypertrophy leads to (and/or results from) the breakdown of the BSCB and entry
of inflammatory cells into the injured cord, ultimately contributing to the onset and
maintenance of neuropathic pain.[25]

C. GFAP is released after CNS injury
GFAP protein is known to be released after SCI and TBI and is proposed to be a
biomarker for CNS injury.[173-176] The release of GFAP, a CNS antigen, after SCI could
disrupt the state of immune tolerance and result in autoantibody production. The process of
the development of autoantibodies after SCI (a “sterile injury”) is proposed to be similar to
immune response to pathogen associated molecular patterns (PAMPs) in bacterial
exposure; however, after a sterile injury development of autoantibodies is in response to
damage associated molecular patterns (DAMPs).[177, 178] Circulating B cells are
recruited by the dying cells, B cells can bind the released self-antigen (GFAP) and the B
cell can be activated by a T cell that is specific for a self-peptide. These B cells differentiate
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into plasma cells secreting autoantibody, the autoantibody further stimulates the
inflammatory response inducing more cell damage and activating more autoreactive B
cells, producing more autoantibody until the damaged cells are cleared.[179] Deficiencies
in the clearance of apoptotic and dying cells after SCI may contribute to loss of B cell
tolerance and result in autoantibody production.[180]
After injury, inflammation is induced in recognition of damage associated molecular
patterns (DAMPs) on the released CNS antigen(s) (e.g., GFAP and CRMP2) that are
detected by pattern-recognition receptors (PRRs) (similar to the mechanism used by
pathogens and PAMPs).[178] Classes of PRRs include Toll-like receptors, NOD-like
receptors, anti-viral RIG-I-like receptors, C-type-lectin receptors with their carbohydratebinding domain and absence in melanoma 2-like receptors (the latter PRR having
involvement in immune responses to bacteria and DNA viruses); PRRs mediate the
DAMP-associated inflammatory response.[180] After tissue damage, PRRs activate
signaling pathways mitogen-activated protein kinase (MAPK), nuclear factor-kB (NF-kB),
and type 1 interferon (IFN-1) which increase pro-inflammatory cytokines (e.g., IL-1, TNF)
and chemokines.[181] IL-1α and IL-33 are released in their precursor, biologically active
form from cells during necrosis leading to the recruitment of neutrophils and alarmins which
alert immune cells.[181]

Uric acid is an example of a pro-inflammatory DAMP that

contributes to inflammation.[182] Post-trauma necrotic cell death resulting in the loss of cell
membrane integrity results in the release of multiple pro-inflammatory endogenous DAMPs
including high-mobility group box 1 (HMBG1), heat shock proteins, S100 proteins, heparin
sulfate, DNA, RNA and others.[181, 183]
Heat shock proteins, S100, uric acid, HMGb1 and heparin sulfate activate Toll-like
receptors expressed on the membranes of dendritic cells and lymphocytes.[181] Dendritic
cells are activated by necrotic cells releasing heat shock protein 70, IL-1α, HMGB-1 which
induce Toll-like receptor-IL-1 signaling.[184] Dendritic cells then present the auto-antigen
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resulting in the potential for formation of autoantibodies.

The development of

autoantibodies has been demonstrated in a sterile injury mouse model of myocardial
infarction which results in ischemia and tissue necrosis causing release of intracellular
contents that cause sterile inflammation.[185] The mouse myocardial infarction model
proved that dendritic cells presented the self-antigen to autoreactive CD4+ T cells which
assumed an autoreactive T-helper cell phenotype, Th1/Th17, promoting autoantibody
production.[184]
DAMPs can bind to an antibody and activate complement through antibody binding
to lipids on the necrotic cell surface, or to released antigen.[177] Complement is also
activated by proteases released from damaged tissue.[186] The complement cascade
results in the activation of inflammatory anaphylatoxins C3a and C5a.[187, 188] Mice
deficient in C3 have a reduced immune response compared to wild type mice.[177]
However, even in the absence of complement, in the context of cell death B cells and
antibodies contribute to inflammation, possibly through uric acid promoting inflammation or
through antibody binding Fc receptors on leukocytes.[177] PAR2 receptor expressed on
leukocytes can induce inflammation and it can be activated by proteases released from
necrotic cells; consistent with this, PAR2 deficient mice had reduced inflammatory
response compared to wild type mice in a cell death-induced model.[177] The PRRs that
activate the Toll-like receptor pathway (e.g.,TLR7 with IFN-1) cause the activation of B
cells and production of autoantibodies.[189, 190]

GFAP that is released after injury could

similarly cause the activation of B cells and the production of autoantibody.
Increased GFAP expression after CNS injury accompanies astrocyte hypertrophy
and activation. Activation of astrocytes leads to the secretion of inflammatory mediators
(IL-1β, IL-6 and TNF-α) and expression of inducible nitric oxide synthase which propagates
the inflammatory state and may potentiate SCI-induced chronic pain.[25]
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The development of an autoantibody that binds to GFAP may contribute to
prolonged BSCB breakdown, continued passage of inflammatory mediators across the
BSCB and potentiate pain. The hypothesis is that autoantibodies to GFAP will be present
after SCI and will be associated with neuropathic pain. The following experiments were
performed to validate the potential of GFAP to be an antigen to which some SCI patient
plasma is immunopositive and assess the relationship to neuropathic pain.

4.2. Methods
A. Spot excision and LC-MS/MS
Immunoreactive spots from 2-D gels were identified and excised from Coomassie
stained gels as described in Chapter 2.13B

Proteins were subjected to LC-MS/MS and

identified as described in Chapter 2.13C.

B. Validation of GFAP antigen, Immunodepletion and western blots

Figure 19. Flow chart of GFAP immunodepletion of brain homogenate

Immunodepletion was performed to prepare IgG-poor and GFAP-poor brain
homogenate as described in Chapter 3.2 C; 25µl anti-GFAP was used in these experiments
to create the beads to deplete GFAP from brain homogenate (Figure 19).
To further validate that the T2 patient samples produced immunoreactivity to GFAP,
western blots were performed as described in Chapter 2.7. These western blots were from
8% acrylamide gels containing purified recombinant GFAP (5µg/well) (OriGene).
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C. Capillary electrophoresis immunoassay and antigen verification
Western analysis and verification of antigen specificity was carried out as described
in Chapter 3.2 D and E. The capillary electrophoresis immunoassay parameters were the
same except GFAP protein (160ng/µl) and plasma dilutions of 1:50 were used and a
custom anti-GFAP antibody (1:20,000) was the positive control. Those plasma samples
that were immunopositive to GFAP were considered as having autoantibodies reactive to
GFAP (GFAPab) if they met the criteria of 1) having immunoreactivity above baseline, 2)
decrease by >30% when pre-blocked with GFAP protein, and 3) immunoreactivity did not
decrease when blocked with a competing protein. Subject samples used in these studies
are described in Chapter 3.2 E.1 and Tables 6 and 7.

D. Receiver Operator Characteristic (ROC) curve analysis
A ROC curve was generated to determine the sensitivity (true positive rate) and
specificity (1- specificity is the false positive rate) of GFAPab at predicting neuropathic pain
within 6 months of SCI at different thresholds. The area under the curve (AUC) generated
from the ROC curve provides an index of how useful GFAPab is at predicting neuropathic
pain.[191] An AUC of 0.5 has no discriminatory ability; generally, an AUC > 80 is good, 70
to 80 is fair, and < 70 is considered a poor predictor.[191]
To estimate the ng/mL of GFAPab present in human plasma a standard curve was
created with the custom anti-GFAP antibody that had a known concentration. The GFAP
sample (160ng/mL) was probed with the custom anti-GFAP antibody (1mg/mL) at
increasing dilutions (1:25,000 to 1:3200,000). A standard curve of the anti-GFAP AUC
immunoreactivity relative to anti-GFAP ng/mL was generated (Figure 20). This curve was
used to estimate the concentration of GFAPab (ng/mL) in plasma from the AUC
measurement that was predictive of future development of neuropathic pain.

The

82

concentration of GFAPab that provided the highest sensitivity and specificity was selected
as the threshold value.
Figure 20 Extrapolation of GFAPab threshold in ng/mL based on GFAPab AUC

Figure 20. Extrapolation of GFAPab threshold in ng/mL. The GFAP protein sample
(160ng/mL) was probed with a custom anti-GFAP antibody (concentration of 1mg/mL)
at increasing dilutions (1:25,000 to 1:3200,000) (lanes 1-8). Two SCI plasma samples
(1:50 (lanes 9-10) and no primary (lane 11) were included as controls. A standard
curve of the anti-GFAP AUC immunoreactivity relative to anti-GFAP ng/mL was
generated (shown above right).

The white circle indicates the threshold level of

GFAPab in patient plasma at 16±7 days that would be predictive of development of
neuropathic pain within 6 months of injury.
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E. Measuring the odds of developing of neuropathic pain when GFAPab
and/or CRMP2ab are present at 16 ± 7 days.
The presence of the two autoantibodies on the the development of neuropathic pain
was analyzed using a chi-square test and an odds ratio was calculated. Multiple logistic
regression was performed while controlling for age, gender, body mass index, complete
injury, and cervical level to evaluate the probability of the GFAPab and/or CRMP2ab
predicting neuropathic pain. Statistical analysis was performed as described in Chapter
2.11.

4.3. Results

A.

Spots excised identified as GFAP.

Seven of the spots sent for LC-MS/MS analysis were positive for GFAP (Chapter
2.13B). The species was correct. Results of peptide matches showed good coverage. For
example, on one spot the sequence coverage was 66.8%. For that spot, the first matched
peptide started with serine 8 (S8) in the N terminal region and the last matched peptide
ended with Lysine 399 (K399) which is in the C terminal region; additionally there were
multiple peptides matched in the rod domain.[192] Consistent with GFAP, these spots
ranged in molecular weight from 38 to 50kDa and pI of between pH 5 to 6. The original 2-D
gel membrane that was used to identify spots for LC-MS/MS analysis was stripped and reprobed with a custom anti-GFAP antibody. There was overlapping reactivity between the
index SCI patient immunoreactivity and the immunoreactivity produced by the custom antiGFAP antibody. This suggested that the patient IgG immunoreactivity and the anti-GFAP
antibody had some commonality.
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B. Validation of immunoreactivity to GFAP.
The brain homogenate and GFAP-depleted homogenate were probed on a western
blot with T2 patient plasma known to be positive for immunoreactivity at 38-50kDa. Brain
homogenate sample depleted of GFAP had less immunoreactivity between 38-50kDa than
the non-GFAP depleted sample. Western blots probed with SCI patient T2 plasma and
custom anti-GFAP demonstrates immunoreactivity to GFAP at 50kDa (Figure 21). These
results are consistent with the findings from the LC-MS/MS showing SCI patient plasma
immunoreactivity to GFAP.

Figure 21. SCI Patient Plasma Immunoreactive to Purified Recombinant GFAP Protein

Figure 21. Representative lanes from a Western blot showing T2 with banding
patterns consistent with positive immunoreactivity to GFAP protein. Lane 1
shows a SCI patient T2 plasma probed against purified recombinant GFAP
protein.

Lane 2 is a custom anti-GFAP antibody generated by the Dash

Laboratory.

These results are consistent with the LC-MS/MS results that

identified GFAP as a potential antigen.

85

C. Capillary electrophoresis immunoassay and antigen verification validates
the presence of GFAPab.
C.1 GFAPab is specific
The previous experiments suggest that the GFAP antigen, identified through 2-D
electrophoresis and LC-MS/MS, produces immunoreactivity at T2 in some SCI patients. In
order to estimate the proportion of the SCI subjects who are positive for GFAPab purified
recombinant human GFAP protein was used as the sample on a capillary electrophoresis–
immunoassay to measure the level of immunoreactivity produced by SCI patient plasma.
Initial studies determined the plasma dilution and amount of protein to use for the assay.
Figure 22 illustrates a SCI patient plasma’s immunoreactivity to increasing amounts of
GFAP (10, 20, 40, 80, 160 ng) and lack of immunoreactivity to a second protein (CRMP2) in
the same amounts. Indiscriminant binding was not seen in this subject.
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Figure 22 Immunoreactivity of a SCI plasma sample specific for GFAP in response to
increasing amounts of GFAP protein and CRMP2 protein.

Figure 22 Immunoreactivity of a SCI plasma sample specific for GFAP in response to increasing
amounts of GFAP protein and CRMP2 protein.
A) Purified recombinant GFAP protein was loaded in increasing amounts on lanes 1-4 (20, 40, 80, 160
ng), purified recombinant CRMP2 protein was loaded in lanes 5-8. Lanes were probed with human
plasma (1:50) from a known GFAPab-positive subject and secondary anti-human HRP IgG.
Immunoreactivity is seen in the GFAP lanes, but not in the CRMP2 lanes.

This subject shows

specificity for GFAP. For this subject the amount of GFAP is the limiting factor as indicated by the
decreasing GFAPab area under the curve at lower amounts of protein.
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To verify antigen-binding specificity, competition studies were performed using
diluted plasma (1:50) by the capillary electrophoresis-immunoassay.

Samples were

incubated overnight at 4°C either with or without 1600ng/10µl of the GFAP protein or an
equimolar amount of a competing protein labeled with the same Myc-DDK tags (purified
CRMP-2) to allow comparison between pre-absorbed samples with the same sample that
underwent standard incubation.

Figure 23 is a representative subject showing

decreased immunoreactivity to GFAP after pre-incubation with GFAP. An immunoreactive
area can be seen, corresponding to the molecular weight of GFAP. Immunoreactivity was
reduced when pre-absorbed with GFAP whereas the pre-incubation with CRMP2 had no
demonstrable effects on the immunoreactivity to GFAP protein. These results are
consistent with the LC-MS/MS findings of GFAP as an antigen, and suggest the
immunoreactivity to GFAP protein is specific.
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Figure 23. SCI patient plasma immunoreactivity specific for GFAP.

Figure 23. SCI patient plasma immunoreactivity specific for
GFAP. A) Image showing SCI plasma immunoreactivity to
GFAP protein (lane 1), plasma pre-blocked with GFAP
(lane 2), plasma pre-blocked with competing protein
(CRMP2) (lane 3), no primary showing no immunoreactivity
(lane

4),

anti-GFAP

positive

control

(lane

5).

Immunoreactivity from plasma is not seen in lane 2 that
was pre-blocked with GFAP, but it is present in the plasma
that was pre-blocked with CRMP2 showing the plasma
antibody in this sample is specific for GFAP. B) AUC of
plasma, pre-blocked plasma and competed plasma. C)
Graphic representation of immunoreactivity change with
pre-incubation of sample.
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C2. GFAPab present in plasma samples
There was no statistically significant difference between GFAPab-positive
and GFAPab-negative SCI patients based on sex, age, weight, complete/incomplete, or
cervical/other level of injury.
For acute SCI patients, plasma samples collected 1.2 ± 0.7, 6.4 ± 1, 16 ± 7 and 96 ±
54 days after injury were assayed. Figure 24 presents the time course for GFAPab levels
following SCI. There was a significant change in GFAPab over time (F(3,37) = 3.42, p=0.02),
with peak levels detected at the 16 day time point. For the 96 day sampling period, only 13
samples were available for testing.

When assessed for the presence or absence of

GFAPab at the 16 day time point, 21 of 38 (55%) acute SCI were found to be
immunopositive.
GFAPab.

By comparison, 4 of 19 (21%) healthy volunteers were positive for

The GFAPab levels measured at the 16 day time point were found to be

significantly increased by comparison to those measured in healthy volunteers (T=401.5,
medians 26,377 vs 0; p=0.005) (Figure 25).
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Figure 24 GFAPab levels after SCI over time

Figure 25. SCI patient plasma levels of GFAPab are significantly different from
those of healthy volunteer controls. (T=401.5, medians 26,377 vs 0; p=0.005)
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Samples from chronic SCI patients (1-41 years post-injury, mean of 15 years) were
assayed for the levels of GFAPab. Of the 80 chronic SCI patients assayed, 34 (42.5%)
were found to be immunopositive for GFAPab. When compared to the healthy volunteers,
chronic SCI GFAPab levels were not significantly different (T=758, medians 0 vs 0,
p=0.052; Figure 26). Sample size calculations based on data from theses chronic SCI and
healthy volunteer subjects shows that 23,091 subjects would be needed to detect a
significant difference at an 80% power with an alpha of 0.05.
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Figure 26. Chronic SCI patient plasma levels of GFAPab compared to healthy volunteer
controls. (T=758, medians 0 vs 0, p=0.052; Figure 27). Sample size calculations based on
data from theses chronic SCI and healthy volunteer subjects shows that 23,091 subjects
would be needed to detect a significant difference at an 80% power with an alpha of 0.05.
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C3. GFAPab in chronic SCI patients does not have diagnostic value for
neuropathic pain.
Neuropathic pain was diagnosed in 46 (57.5%) chronic SCI subjects and they were
classified as positive for neuropathic pain, whereas 34 (42.5%) of the chronic SCI patients
were classified as not having neuropathic pain.

GFAPab levels at the time of pain

assessment could not distinguish between chronic subjects with or without neuropathic pain
(T=1507, medians 0 vs 7898.5; p=0.16).

When evaluated using a receiver operating

characteristic (ROC) curve, chronic SCI GFAPab was found to have no diagnostic value
(AUC = 0.42) in identifying chronic patients with neuropathic pain.

D. ROC curve analysis shows GFAPab levels distinguish acute patients
who develop neuropathic pain versus those who do not.
In acute SCI patients, neuropathic pain was defined by a clinical diagnosis within 6
months of injury. Figure 27 shows GFAPab levels over time by pain group. Using the
GFAPab levels measured at the 16 day time point, acute SCI subjects with neuropathic
pain within 6 months had higher GFAPab levels than those without neuropathic pain
(T=219, p=0.02) (Figure 28). There was a positive correlation between the presence of
GFAPab at 16 ± 7 days and the development of neuropathic pain (r=0.46, p=0.003).
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6 months of injury (p=0.02)

Figure 27. GFAPab level by pain group. The GFAPab level is significantly elevated at 16±7 days in those who develop pain within

Figure 28. GFAPab level is significantly higher at 16±7 days post-SCI in patients
who develop neuropathic pain within 6 months of SCI; T=219, p=0.02.
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ROC analysis shows that GFAPab levels have a predictive value of 0.71 (95% CI,
0.53-0.89 p=0.03) for the development of neuropathic pain within 6 months after injury
(Figure 29 A). Using a cut-off of 36 ng/mL (AUC=10,208) at 16 ± 7 days post-SCI, GFAPab
had 74% sensitivity and 73% specificity for predicting neuropathic pain within 6 months of
SCI (95% CI, 0.52-0.9 for sensitivity, 0.45-0.92 for specificity)( Figure 29 B).
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Figure 29. Receiver operator characteristic analysis of predictive value of GFAPab for the
development of neuropathic pain within 6 months of spinal cord injury.
A) Receiver operator
characteristic analysis
shows that GFAPab levels
have a predictive value of
0.71 (95% CI, 0.53-0.89
p=0.03) for the
development of
neuropathic pain within 6
months after injury.

B) Using a cut-off of 36
ng/mL

(AUC=10,208)

at

16±7 days post-SCI had
74% sensitivity and 73%
specificity

for

predicting

neuropathic pain within 6
months of SCI (95% CI,
0.52-0.9

for

sensitivity,

0.45-0.92 for specificity).

99

E.

Predictive utility of GFAPab and CRMP2ab for the development of

neuropathic pain after SCI.
These experiments identified two autoantibodies that are present in circulationg
plasma of people with SCI.

The peak immunoreactivity for the longitudinally collected

samples was detected at 16 ± 7 days. Recognizing that no one autoantibody is likely to be
the sole predictor of the development of neuropathic pain, the effect of the presence of the
two autoantibodies on the the development of neuropathic pain was analyzed (Figure 30).
A chi-square test was performed and a significant relationship was found between the
presence of autoantibodies and the development of neuropathic pain, X2 (1, N=38)=7.47,
p=0.006. The presence of either or both antibodies at 16 ± 7 days post-SCI significantly
increases the odds of developing neuropathic pain within 6 months by 9.5 times among
those with SCI (95% CI, 2.08-43.50, p=0.006). When controlling for age, gender, body
mass index, complete injury, and cervical level, the presence of GFAPab and/or CRMP2ab
remains a significant factor in predicting neuropathic pain within 6 months with an odds ratio
of 15.3 (95% CI 1.9 to 125, p=0.01).

Figure 30. Panel of autoantibodies.
There were 24/38 (63%) of SCI subjects positive for one or both autoantibodies. A significant
relationship was found between the presence of autoantibodies and the development of
neuropathic pain, X2 (1, N=38)=7.47, p=0.006. The presence of GFAPab and/or CRMP2ab
increased the odds of developing neuropathic pain within 6 months of injury by 9.5 times.
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4.4. Discussion
A. Key findings
1. GFAPab was present in 21/38 (55%) of acute SCI subjects, 34/80 (43%) chronic
SCI subjects and 4/19 (21%) of healthy control volunteers.
2. The level of GFAPab in the acute SCI subjects was significantly higher than that
of healthy volunteers and chronic SCI subjects with the 16 ± 7 day sample showing peak
levels.
3.

GFAPab levels in chronic SCI subjects were not significantly higher than

GFAPab levels of healthy volunteers (T=758, p=0.052). It is possible that the timing of the
acquisition of the sample, an average of 15 years after SCI, influenced the level of the
GFAPab present in the plasma.
4.

In chronic SCI patients, 46/80 (58%) had neuropathic pain at the time of

sampling (1-41 years post-SCI). No difference in the levels of GFAPab could be detected
in the chronic SCI patients with neuropathic pain compared to those without neuropathic
pain.
5. There were significantly higher levels of GFAPab in the 16±7 day plasma of
acute SCI patients who developed neuropathic pain (23/38, 60.5%) compared to those who
did not develop neuropathic pain (15/38, 39.5%) within 6 months of injury and there was a
positive correlation between the presence of GFAPab and the development of neuropathic
pain.
6. When combining the presence of GFAPab with CRMP2ab at 16 days post-SCI
the odds of developing neuropathic pain within 6 months was significantly higher (OR 9.5,
95% CI 2.08 to 43.50, p=0.006). This remained significant after controlling for age, gender,
body mass index, complete injury, and cervical level (OR 15.3 95% CI 1.9 to 125, p=0.01).
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B. There was more than one GFAP spot identified on 2-D gels
Seven of the spots sent for LC-MS/MS analysis were positive for GFAPab. These
spots ranged in molecular weight from 38 to 50kDa and pI of between pH 5 to 6.
Consistent with the LC-MS/MS findings (Methods 2.13 C), GFAP and its breakdown
products have molecular mass of approximately 38-51kDa and a basal pI of pH 5.4. [192]
The human CNS expresses 8 highly homologous GFAP isoforms (α, γ, δ/ε, κ, ∆135, ∆164,
∆exon6, ∆exon7).[169, 193] It is possible that the range of immunoreactivity seen in SCI
patient samples represents recognition of different homologous isoforms. A recent study
identified 22 of 451 (5%) patients with neurological autoimmune disease as having
antibodies to GFAPα, 14 of these 22 patients were also immunopositive for GFAPδ.[194]
Ishida et al. performed 2-D western blotting analysis comparing immunostaining of
patients with autoimmune dementia to vascular dementia patients and to a standard antiGFAP antibody. A broad range of pIs existed in the patients’ immunoreactivity, and the
patients with autoimmune dementia had more alkaline (high) pIs than those of the
commercial antibody or of vascular dementia patients’ immunoreactivity.[195] The
differences in pIs are related to the degree of phosphorylation, with higher phosphorylation,
GFAP becomes more acidic.[195] Different patients may form autoantibodies to different
post-translational modifications of GFAP. The Ishida et al. commercial anti-GFAP, the
custom anti-GFAP and SCI patients in the present study showed immunoreactivity at the
size of intact GFAP as well as to degradation products of lower molecular weights. The
Ishida et al. patients’ immunoreactivity ranged between 40-58kDa, similarly the spots
identified as GFAP evaluated on patients in the present study ranged from 38 to 50kDa.
Truncated GFAP at 38-48kDa in addition to the intact 50kDa protein on western blot has
been reported and it was suggesting the immunoreactivity recognized GFAP that had
undergone postmortem proteolysis in the CNS homogenate.[192] Calpain cleavage of
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GFAP to 38kDa was reported in a TBI study which proposed that the 38kDa fragment was
the primary autoantigen inducing an autoimmune response.[196]

C. Some healthy volunteers have GFAPab
Four healthy volunteers were found to have detectable GFAPab.

All healthy

volunteers represented themselves as healthy. A history of prior TBI and/or concussion
was not recorded at the time of sample collection; therefore it is unclear if the levels of
GFAPab seen in these patients were due to a previous, undocumented CNS injury,
neurosurgical procedure or an ongoing inflammatory disease state.
A study of TBI patients who had autoantibodies to GFAP found 64.2% (34/53) of
their TBI subjects 10 days post-injury and 15.2% (15/96) of healthy controls were positive
for GFAP autoantibodies.[196] The TBI patients’ serum GFAP level at 1 day after injury and
GFAP autoantibodies 4 to 10 days post injury was correlated (p=0.048).[196] GFAP
autoantibodies have also been identified in patients with neoplasms (breast, ovarian and
brain (GBM) cancer and thymoma).[194] Additionally, GFAP autoantibodies were reported
in diabetes type I and type II. [197, 198] There was no relationship found with GFAPab or
neuropathic pain in chronic or acute SCI coupled with a diagnosis of diabetes in the present
study; however, there were only one acute SCI and 5 chronic SCI subjects with diabetes. It
is not known if any of the SCI subjects or healthy volunteers developed diabetes after the
study ended. Diabetes studies evaluating the correlation of the presence of GFAPab with
the development of diabetic neuropathy and neuropathic pain are unreported in the
literature.

D. Potential role of GFAP autoantibodies in developing neuropathic
pain
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SCI causes a breakdown of the BSCB that allows for the infiltration of circulating
cells and molecules into the injured cord, and also allows the efflux of cellular debris and
proteins.[199, 200] Consistent with this, it has been previously reported that the astrocytic
protein GFAP can be detected in the plasma of SCI patients.[201, 202] However, there
was no correlation between neuropathic pain at 6 months and CSF GFAP protein levels at
24 hours.[202]
The peak levels of GFAPab occurred at 16 ± 7 days after SCI. It is possible that the
early availability of GFAPab contributes to the development of neuropathic pain and that
once its action has transpired, it may no longer be required to maintain neuropathic pain.
Alternatively, GFAPab could contribute to a continuously permeable BSCB.

The presence

of antibody fostering ongoing inflammation could lead to a perpetually permeable BSCB
and promote neuropathic pain.[25]
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Chapter 5. Complement Components C3 and C5

5.1. Introduction
A. What is complement?
The complement system includes over 40 proteins that function together to defend
the host against pathogens and infection through a coordinated cascade of processes that
opsonize pathogens, clear host cells after apoptosis, clear immune complexes and
enhance antibody response.[187] Complement is made primarily in the liver and circulates
in blood in its inactive form. After SCI, activation of complement is initiated by the trauma
to the tissue. In this context, complement activation is involved in clearing apoptotic cells
and neuronal or glial cell fragments.[23] Activated components can be found at the injury
site as well as in systemic circulation.[45]
There are three main complement pathways (classical, lectin and alternative) that
converge at complement component C3. The classical pathway is initiated by the binding
of complement C1q to immune complexes or to pathogen-associated molecular patterns
(PAMPs) on pathogen surfaces which initiates a conformational change that activates C1r
and C1s leading to cleavage of C2 and C4 resulting in C4b-C2a (the C3 convertase).[203]
The lectin pathway detects PAMPS or damage-associated molecular patterns (DAMPs, on
damaged host cell surfaces) through mannose-binding lectin (MBL) or ficolins which
causes the mannose-binding lectin-associated serine proteases (MASPs) to activate C2
and C4 resulting in the formation of C3 convertase.[203] The alternative pathway is
activated spontaneously through C3 hydrolysis. With C3 hydrolysis, C3b binds to
complement factor B (FB) forming C3b-B which, when activated, is processed by
complement factor D (FD) resulting in alternative pathway C3 convertase (C3b-Bb).[203]
(Complement can also be activated through the coagulation cascade.[204])
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The cleavage of C3 by C3 convertases leads to activation of C3a, opsonization and
clearance of pathogens, and activation of C5. C5 is the target component which is cleaved
by the C5 convertase complexes leading to C5a release and the initiation of the membrane
attack complex (MAC) pathway which culminates in cell lysis and death. Normally,
complement regulatory molecules present on host cells (e.g., membrane cofactor protein,
or complement receptor 1) and plasma regulators (factor H) protect the host cells against
complement activation against host cells.[187] (Figure 31, adapted from[187, 203, 205]).
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Figure 31 Model of Complement Cascade

Figure 31. Model of the complement cascade. The complement cascade is an important host
defense mechanism against infection and disease. There are three main activation pathways of the
complement cascade, the classical, lectin and alternative pathways. The pathways have different
initiators of activation; however they converge at complement C3.

The cleavage of C3 by C3

convertases leads to activation of C3a, opsonization and clearance of pathogens, and activation of
C5. C5 is the target component which is cleaved by the C5 convertase complexes leading to C5a
release and the initiation of the MAC pathway which culminates in cell lysis and death. (MBL,
mannose binding lectin; MASP, mannose-binding lectin-associated serine proteases; FB,
complement factor B; FD, complement factor D; MAC, membrane attack complex.)
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Complement anaphylatoxins C3a and C5a are chemotactic mediators that lead to
the activation of immune cells.[203] C3a and C5a stimulate polymorphonuclear cells (e.g.,
neutrophils, eosinophils, and mast cells) to release histamine and arachidonic acid
metabolites (prostaglandins, leukotrienes and lipoxins), all of which are critical in events
occurring during tissue damage. The histamine release causes vasodilation, enhanced
vascular permeability and endothelial activation; prostaglandins contribute to vasodilation,
pain and fever; leukotrienes also increase vascular permeability, chemotaxis and leukocyte
adhesion and activation; lipoxins act as antagonists to leukotrienes.[206]

The increased

vascular permeability and leukocyte and endothelial activation contribute to increased
blood-spinal cord (BSCB) permeability after SCI.
Complement activation contributes to inflammation as part of the innate immune
response and provides a bridge to the adaptive immune system through interactions with
B- and T cells.[203, 207, 208] Complement C1q activates complement by binding to the Fc
portion of surface-bound antibodies and immune complexes.[205] Complement C3 binds to
circulating B- and T-lymphocytes and dendritic cells.

Complement also produces pro-

inflammatory effects through complement anaphylatoxins (C3a and C5a). [188, 209, 210]
The combined presentation of complement receptors and B cell antigens enhances the
activation of B cells.[211] Complement clears the immune complexes of B cell produced
pathogen-specific antibodies and the pathogen antigen.[187]

B. Complement activation and neuropathic pain
Increased complement component concentrations have been associated with
neuropathic pain, related in part to the pro-inflammatory effects of complement discussed
previously.

Chronic constriction of the sciatic nerve in a rat model demonstrated

increased C3 mRNA expression in the spinal dorsal horn as measured by RT-PCR that
was correlated with hyperalgesia (r=0.899, p<0.0001).[23] The levels of dorsal horn C3
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mRNA increased over the 7 days evaluated and these increases corresponded with the
development of hyperalgesia. C3 immunoreactivity was also increased by 2-fold and C3
concentration in spinal cord homogenate was up to 3.5-fold higher in the injured rats
compared to sham controls. The level of circulating C3 was 300-fold greater than the CSF
C3 level, suggesting that a breech in the BSCB allowed complement components to
penetrate the BSCB, thus elevating the concentration of complement in the cord. GFAP (a
marker for activated astrocytes) was also increased in the spinal cord in the injured rats
with hyperalgesia.[23]
After SCI a positive feedback cycle is created from the elevated levels of
complement accumulated at the injury site that stimulates the release of inflammatory
mediators which then further activate the complement cascade.[187]

The activated

complement perpetuates increased vascular permeability, leukocyte recruitment and
activation, pain and sustained tissue damage.
Using three distinct peripheral nerve injury models (chronic constriction injury,
sciatic inflammatory neuropathy, intrathecal injection of HIV-1) Twining et al. administered
an intrathecal complement inhibitor (soluble human complement receptor type 1) that
blocked C3a, C5a and the formation of the MAC.

Use of the complement inhibitor

correlated well with the elimination of the mechanical allodynia that was induced in all three
different peripheral injury models.[212] Griffin et al. performed a gene chip screen on RNA
from dorsal horn in peripheral neuropathic pain rat models and identified an increase of
genes expressing complement proteins (C1qb, C1qg, C4 and C3).[213] The relationships
of complement components C5, C5a, C5b and C6 to pain sensitivity were evaluated. C5a
was injected into the intrathecal space of uninjured rats which induced cold pain sensitivity;
additionally, a C5a receptor antagonist injected into the intrathecal space of peripheral
nerve injured rats resulted in decreased cold hypersensitivity.[213] C5-deficient mice with
peripheral nerve injury had decreased pain sensitivity, whereas C6-deficient rats with
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peripheral nerve injury (C6 is downstream of C5b) had no change in pain sensitivity leading
to the conclusion that in this model C5a mediates neuropathic pain. [213]
Overall, these experimental models show a strong relationship of complement
components C3 and C5 mediating the development of trauma-induced neuropathic
pain.[23, 210, 212, 213]

Data presented here indicate that after SCI some patients

develop CRMP2ab and GFAPab and that there is an association between GFAPab at
16±7 days and neuropathic pain within 6 months of SCI. Complement and complement
breakdown may be contributing to the association seen between the GFAPab and the
development of neuropathic pain after SCI. Supporting this, impaired clearance of antigenantibody complexes from deficiencies in complement increases the risk of developing an
immune complex-mediated disease such as in systemic lupus erythematosus (SLE).[214,
215] Complement activation after SCI is expected. The physical damage to the cells is the
cause of complement activation and complement infiltrates to the injury site.[216]
Therefore, analyses were performed to test whether SCI results in a reduction in the
circulating levels of complement C3 or C5 in human patients reflecting complement
migration of C3 or C5 to the site of injury.
The overriding hypothesis is that complement components and their subsequent
cascade related components contribute to the association between the GFAPab and the
development of neuropathic pain.

However, as results below show, a reduction in

complement after the initial complement activation was not observed in the present study.

5.2. Methods

A. Plasma collection and patient classification
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Plasma from consented acute SCI patients was collected as described in Method
2.3. Patients were classified according to the presence or absence of neuropathic pain as
described in Method 2.2.

B. Enzyme-linked immunosorbent assay (ELISA)
Complement C3 and C5 levels were evaluated in the acute SCI plasma samples to
determine whether there was an association with plasma levels of these proteins with the
presence of GFAPab, CRMP2ab or the development of neuropathic pain. To evaluate
levels of complement C3 and C5, enzyme-linked immunosorbent assays (ELISA) were
performed according to the manufacturer’s instructions (abcam ab108822 and ab125963).
Plasma previously collected in EDTA tubes and frozen at -80◦C was diluted 1:800 for
complement C3 and 1:20,000 for complement C5 assay.
assayed in duplicate on 96-well plates.

Each plasma sample was

For the C3 assay plasma or standard were

incubated for 2 hours with biotin followed by washing, then streptavidin-peroxidase
conjugate was added to each well, incubated for 30 minutes and washed. For the C5
sandwich ELISA, sample or standard was added to each well and allowed to incubate for 2
hours. The plate was washed and then biotin was added and allowed to incubate for one
hour. This was followed by washing; streptavidin-peroxidase conjugate was added to each
well, incubated for 30 minutes and washed.

After the last wash for both assays,

tetramethylbenzidine (TMB) was added followed by the stop solution and the absorbance
was read at 450nm with a correction at 540nm. The calculation of unknown concentrations
from the standard curve was performed using Systat Software, Inc. SigmaPlot for Windows
(San Jose, CA). The minimum detectable threshold of the Complement C3 assay is
0.2µg/mL and normal plasma levels range from 900 to 1900 µg/mL.[217, 218] The assay
minimum detectable threshold of Complement C5 is 0.1ng/mL and normal plasma levels
are 65µg/mL(abcam).[219, 220]
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Statistical analysis was performed as described in Chapter 2.11.

5.3. Results
A. Complement C3 or C5 are activated after SCI
Plasma levels of complement C3 and C5 were measured using ELISAs. Median
values for complement C3 were 472.3 µg/ml for healthy volunteers and 673µg/mL, 901.3
µg/mL and 970.9 µg/mL for 1.2, 6.4 and 16 days post-SCI, respectively. There was a
significant increase in the C3 levels between 1.2 days and C3 levels at 6.5 and 16 days
(F(2,37)=34.1, P<0.001). The levels of C3 at 1.2 days compared to healthy volunteers was
not significantly different (T=77, p=0.056). At the 6.4 and 16 day time point, C3 was
significantly elevated compared to healthy volunteers (6.4 day: T= 32, p<0.001; 16 day:
T=33, p<0.001).
Median values for complement C5 were 96 µg/mL for healthy volunteers and
130µg/mL, 188µg/mL and 189.8 µg/mL for 1.2, 6.4 and 16 days post-SCI, respectively.
There was a significant increase in C5 levels between 1.2 days and C5 levels at 6.5 and 16
days after SCI (F(2,37)=36.7, p<0.001). The levels of C5 at 1.2 day compared to healthy
volunteer samples was not significantly different (T=76, p=0.052). C5 was significantly
higher at the 6.4 and 16 day time points compared to healthy volunteer levels (6.4 day:
T=35, p<0.001; 16 days T=35, p<0.001) (Figure 32).

B. A correlation is observed between the levels of complement C3 but not C5
with the levels of GFAPab and CRMP2ab.
Assessments were made to test whether there is a correlation between the levels of
C3 or C5 and the levels of GFAPab or CRMP2ab at each time point. There is a positive
correlation between the 6.4 day levels of complement C3 and GFAPab levels at 16 days
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(r(34)=0.34, p=0.04), but not any other time point. There is a positive correlation between
levels of C3 and CRMP2ab at 16 days (r(31) = 0.41, p=0.02), but not at any other time
point.
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Figure 32. Complement C3 and C5 levels in SCI patient plasma over time compared
to healthy volunteer control levels. C3 and C5 are significantly elevated at the 6 and
16 day time points. C3: (F(2,37)=34.1, P<0.001); C5: (F(2,37)=36.7, p<0.001)

114

C. An association is not found between complement C3 or C5 with the
development of neuropathic pain
Complement C3 or C5 levels are not different between those who developed
neuropathic pain compared to those who did not (Figure 33). There is not a significant
difference in levels of C3 by pain group F(1,35)=0.48, p=0.49 and there is not a statistically
significant interaction between pain group and time F(2,35)=0.004, p=1. For C5 levels,
there is also no significant difference in C5 levels by pain group F(1,35)=0.49, p=0.49, and
there is not a statistically significant interaction between pain group and time F(2,35)=0.58,
p=0.57.
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Figure 33. Complement C3 and C5 levels did not differ by pain group. There is not a
significant difference in levels of C3 by pain group F(1,35)=0.48, p=0.49 and there is not
a statistically significant interaction between pain group and time F(2,35)=0.004, p=1.
For C5 levels, there is also no significant difference in C5 levels by pain group
F(1,35)=0.49, p=0.49, and there is not a statistically significant interaction between pain
group and time F(2,35)=0.58, p=0.57.
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5.4 Discussion
A. Key Findings
Plasma levels of complement C3 and C5 were increased after SCI through the 16
day time point. Complement C3 and C5 levels did not differ by pain group.

B. Elevation of complement C3 and C5 after SCI.
Contrary to the hypothesis, circulating complement levels did not decrease, but
rather increased over time after injury. It was hypothesized that circulating C3 and C5
levels would decrease as they migrated to the injury site. Alternatively, the upregulation of
C3 and C5 may be the result of ongoing inflammation.
Anderson et al. evaluated the deposition of complement components C1q, C4,
Factor B (binds C3b) and MAC (C5b-9) in the spinal cords of SCI rats experiencing mild or
severe contusion injuries compared to laminectomy-only rats at 1, 7 and 42 days postSCI.[216] These time points are similar to the time points assessed in the acute SCI
human subjects’ circulating plasma. The Anderson et al. study discovered complement
components C1q, C4, FB, C5b-9 activated and peaked within one day, and complement
remained immunoreactive in the injured spinal cord for 6 weeks post-SCI. There was
uniform magnitude of complement component staining both rostral and caudal of the lesion
epicenter (>20mm) in SCI rats, but no immunoreactivity in the laminectomy controls.
Changes due to BSCB permeability in the lateral or ventral white matter were not observed
until 14 days, yet the complement immunoreactivity was present in gray and white matter at
all levels of the spinal cord within one day, thus the authors concluded that BSCB
permeability was not the only source of complement migration and that local complement
synthesis was likely to have been enhanced by inflammatory mediators.[216] In addition to
circulating blood complement permeating the BSCB and complement being produced

117

locally in spinal cord astrocytes, microglia and neurons, complement is found in
polymorphonuclear leukocytes (PMN). C1q, C3, and C5b-9 were associated with PMN
infiltration near the epicenter of the spinal cord.[221] PMN were detected at two hours,
peaked at 24 hours and could still be detected by flow cytometry analysis 6 months after
SCI. Three days after SCI at least 70% of PMNs infiltrating the spinal cord were associated
with C1q or C3 and 95% were associated with C5b-9.[221] A study of 34 acute trauma
victims that evaluated circulating C3a and C3 levels at multiple time points up to 7 days
post-injury found an association with higher circulating C3a levels and non-survival only at
the sample taken within 37 minutes after injury (p=0.008) and the C3a/C3 ratio was higher
in non-survivors than survivors at about 1 hour post-injury (p=0.033).[222] The level of
activation, not the duration of activation was related to non-survival. The acute trauma
study indicated that complement activation occured almost immediately after injury and
peaked early. Based on the timing of peak complement levels in the above studies, it is
possible that a dip in circulating complement would have been missed with the three time
points measured here. Alternatively, the local production may have supplemented
circulating levels to sustain complement levels.

C.

No association found between complement C3 and C5 levels and

neuropathic pain.
The circulating C3 and C5 levels in SCI human subjects were elevated during the 30
days measured; however, there is no association with the presence of neuropathic pain
within 6 months. It is possible that the timing of the complement measurements were too
remote from the later determination of neuropathic pain and that if complement was
measured at 6 months in the neuropathic pain patients it may have been elevated
compared to those without pain.
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Chapter 6. General Discussion

A. Summary of findings
The primary finding from this investigation is that SCI patients who developed
CRMP2ab and/or GFAPab at 16 days had 9.5 times greater odds of developing
neuropathic pain than patients who did not develop these autoantibodies.

Additional

findings include: 1) 34/80 (43%) of chronic SCI patients had GFAPab. 2) Autoantibody
levels peaked at 16 ± 7 days and returned to healthy volunteer levels by 96 ± 54 days after
SCI. 3) At 16 ± 7 days after SCI 8/35 (23%) patients developed CRMP2ab and 21/38
(55%) patients developed GFAPab. 4) The presence of GFAPab at 16 ± 7 days after SCI is
a predictor of the development of neuropathic pain. 5) C3 and C5 remained elevated
through 16 ± 7 days after SCI.
Inflammation has been identified as a contributing factor to the development of
neuropathic pain after SCI.[102, 113, 223] After SCI, inflammation is initiated by the
physical injury and the local immune response. Trauma results in cell damage which
triggers an innate immune response to activate the complement system.[216] Complement
enhances the ability of antibodies and phagocytes to clear cellular debris and pathogens,
and it promotes inflammation as C3a and C5a are activated.[187]

C3a and C5a

anaphylatoxins stimulate neutrophils, eosinophils, and mast cells to release histamine and
arachidonic acid metabolites (prostaglandins, leukotrienes).[187]

Histamine promotes

vasodilation, enhanced vascular permeability and endothelial activation; prostaglandins
produce vasodilation, pain and fever; leukotrienes promote vascular permeability,
chemotaxis, leukocyte adhesion and activation. The increase vascular permeability,
leukocyte and endothelial activation augmented by the mechanical damage from the injury
results in a permeable BSCB. [187] Increased permeability of the BSCB promotes the
119

activation of resident CNS immune cells. Cellular debris is transported to lymphoid organs
for processing by immune dendritic cells enabling lymphocyte activation and the opportunity
to generate autoantibodies.[214] Supporting this, B cells were present in the area of the
lesions after SCI in mice and are also found in the CNS in humans with multiple sclerosis,
an autoimmune disease.[9, 224] Astrocytes and infiltrating monocytes supply factors (B
cell-activating factor (BAFF), and proliferation-inducing ligand (APRIL)) that are required for
B cell functions (survival, differentiation, and germinal formation) and contribute to clonal
expansion of B cells in situ.[225] This creates a favorable environment for autoantibody
production.[225]
Autoantibodies that develop as part of the immune response after SCI have been
identified as contributing to enhanced tissue damage and poor outcome.[9] B cells have
been demonstrated to be causative of SCI pathology through 1) improved functional,
behavioral and tissue recovery from SCI in B cell knockout mice compared to wild type
mice; and 2) that B cell-mediated neurotoxicity is cause by SCI rodent IgG as injection of
SCI IgG into uninjured mice resulted in SCI-like pathology.[5, 9] Until now, the identities of
autoantibodies associated with the development of neuropathic pain in human SCI have not
been identified. The hypothesis is that proteins from the injured spinal cord released by
SCI trigger autoantibody production, which can lead to the development of NP. GFAP and
CRPM2 are two antigens identified as inducing immunoreactivity from SCI patient plasma
samples.

SCI patients who developed CRMP2ab and/or GFAPab had 9.5 times greater odds of
developing

neuropathic

pain

than

patients

who

did

not

develop

these

autoantibodies.
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Antibodies found in human blood vary between individuals based on their lifetime of
variable exposures to pathogens, autoantigens, and other antigens. Autoimmune diseases
have been characterized by the presence of patterns of autoantibodies.

A panel of

autoantibodies is likely to be more powerful than a single autoantibody to supplement or
predict the clinical diagnosis of neuropathic pain after SCI. GFAPab and CRMP2ab are
two autoantibodies that combined show a 9.5 times increased odds of developing
neuropathic pain after SCI and when controlling for injury factors. The injuries being
complete and/or at the cervical level were not associated with the development of the two
autoantibodies.
Systemic lupus erythematous (SLE) is a chronic autoimmune disease affecting
multiple organs including the skin, heart, lungs, kidneys, joints, and nervous system. SLE
is an example of an autoimmune disease that is diagnosed based on clinical findings that
are supplemented with results from evaluations of panels of autoantibodies including
antinuclear antibodies, anti-double stranded DNA and other autoantibodies.

Antinuclear

antibodies are approximately 90% sensitive, but not very specific for SLE whereas antidouble stranded DNA is over 95% specific.[226] The panel of autoantibodies for SLE
balances sensitivity and specificity to enhance the ability to distinguish SLE from other
autoimmune conditions. When the panel of autoantibodies is combined it provides data on
which to determine the presence of disease. For neuropathic pain after SCI, additional
autoantibodies may improve the sensitivity and specificity in order to distinguish who will
develop neuropathic pain. If the current findings are validated this panel of autoantibodies
could be used as a biomarker for early diagnosis.

Forty-three percent of chronic SCI patients have GFAPab
The presence of circulating GFAPab was found in 43% of chronic SCI patients.
ISNCSCI scores, age, sex and weight were comparable for both autoantibody- positive and
121

negative chronic SCI patients indicating the populations were similar.

However, it is

unclear why only a portion of chronic SCI patients generated GFAPab while others did not.
It is possible that the autoantibody negative patients may not have been exposed to
plasma GFAP levels sufficient to mount an immune response (either as primary or
secondary exposure). When evaluating the levels of GFAPab in chronic SCI a difference in
the levels of GFAPab between the pain groups was not detected. The chronic patients
ranged from 1 to 41 years post-SCI. It is possible that the autoantibody-negative patients
produced antibodies at other times. For example, blood levels of IgG antibodies in humans
after receiving a tetanus toxoid boost increased by a factor of 80 between days 5-8 after
injection then decreased after about 2 months reflecting production of short-lived plasma
cells.[227] Short-lived plasma cells have an approximate half-life of human IgG of about 20
days, and long-lived plasma cells have a half-life of about 40 days.[227] Memory B cells
can be antigen-dependent resulting in extensive proliferation and differentiation toward
short-lived plasma cells, or polyclonal responding to

polyclonal activators where all

memory B cells respond undergoing continuous proliferation and differentiation maintaining
a steady state.[227] The chronic subjects enrolled in this study were excluded if they had
known ongoing inflammation (e.g., infection, cancer, skin breakdown, deep vein
thrombosis), and they were on average 15 years post-SCI. These exclusion criteria may
have reduced the ability to measure both short term serological memory (antigendependent) and long-term serological memory (antigen-independent polyclonal activation
and differentiation of memory B cells).[227] It is possible that their GFAPab levels were
below the assay’s limit of detection at the time that their sample was acquired, years after
autoantigen exposure.
The number of active memory cells is influenced by stimulation from cytokines (e.g.,
IL-2, IL-10, IL-21).[228-230] Antigen-specific immune responses directed at other noncross reacting antigens impact the level of these cytokines, which then effects the volume
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of active memory cells.[231] IL-2, IL-10, anti-CD40 and IL-21 induce plasma cell
differentiation from memory B cells, and levels of these cytokines are higher in times of
active inflammation.[230, 232-235] Chronic SCI subjects were excluded if there was a
known, active ongoing inflammatory process. It is possible that excluding those subjects
created a subject selection bias reducing the percentage of chronic SCI with perceptible
GFAPab levels.

Autoantibody levels peaked at 16 ± 7 days and returned to healthy volunteer levels
by 96 ± 54 days after SCI.
On exposure to an antigen lymphocytes with the antigen-specific receptor are
activated and proliferate. Over a period of about 5 days B lymphocytes go through clonal
expansion where they differentiate into effector cells.[179] The differentiated plasma B
cells secrete antibody into the circulating blood as a response in order to clear the
antigen.[236] Most plasma B cells die after the antigen is eliminated, but some of these
antigen-specific B cells remain as memory cells and can be activated quickly.[237] For SCI
subjects, the GFAPab secreted through activation of the memory B cells would require
antigen stimulus to progress though the clonal expansion process.[227, 236] The peak
levels of antibody detected in these samples were found to be at the 16 ± 7 day time point.
These peak levels were generally higher than those observed in samples collected during
the chronic stage of injury.

Of exception, four of the chronic SCI subjects with levels of

GFAPab that were more comparable to that seen acutely after SCI had evidence of
disruption of the BSCB (e.g., recent placement of intrathecal pumps), suggesting a reexposure to antigen may be responsible for the increased GFAPab levels observed in
these patients.[227] Three of these four patients had neuropathic pain.
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At 16 ± 7 days after SCI 8/35 (23%) patients developed CRMP2ab and 21/38 (55%)
patients developed GFAPab.
Although the exact time course of GFAP release in humans after SCI has not been
established, GFAP levels can be detected in the serum of traumatic brain injury patients
within hours of the injury, returning to baseline by 3 days post injury.[174] In rat cortical and
hippocampal brain tissue after controlled cortical impact CRMP2 decreased from 6 hours to
3 days, returning to normal levels by 5 days; the CRMP-2 55kDa breakdown products
showed a corresponding increase over this time period.[156] Circulating levels of CRMP2
were not provided, but this breakdown of CRMP2 indicates that substrate could be
available for autoantibody production after injury. Samples were not available for most
patients within the very early time post-SCI in order to measure early release of GFAP or
CRMP2.
After SCI astrocytes become reactive astrocytes. These reactive astrocytes have
increased size, increased GFAP expression and increased number.[238] Recent analyses
of rat tissue, CSF and serum showed release of GFAP protein and its breakdown products
after SCI that was measurable at 4 hours, 24 hours, and 7 days post-SCI. Elevated GFAP/
breakdown product levels persisted at the injury site and in the serum longer than in the
CSF. There was a positive association with injury severity and CSF and serum levels of
GFAP/breakdown product.[239] The presence of GFAP/breakdown product after injury
would facilitate the development of an autoantibody. In a TBI study, plasma taken within
24hrs of injury from TBI patients was compared with age-matched controls.[240] A new,
specific IgG autoantibody response would not be expected to manifest this close to time of
injury. In agreement with this, it has been reported TBI subjects who had previous TBI with
loss of consciousness had significantly higher levels of GFAPab compared to controls, but
TBI patients who had not had previous injury did not have a significant difference from
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controls at that early time point. [240] This is one example of why some subjects may have
antibodies to GFAP within a day of injury.
Twenty-three percent of SCI subjects had CRMP2ab at 16±7 days after SCI. These
results did not demonstrate significance for an association of CRMP2ab with the
development of neuropathic pain at this peak immune response time point (T=231.0,
p=0.08). The subjects who were CRMP2ab positive with neuropathic pain represented
88% of CRMP2ab positive subjects and the CRMP2ab negative subjects who had
neuropathic pain were 48% of CRMP2ab negative subjects. Sample size analysis based
on these data indicates a larger sample size of 64 subjects is needed to detect a significant
difference at an 80% power with an alpha of 0.05.
CRMP2 is a cytoplasmic protein found in central and peripheral axons.[155] CRMPs
participate in semaphorin-induced growth-cone collapse and influence the direction of axon
growth,

dorsal

root

ganglion

neuron growth,

dendrite

specification,

and

axon

regeneration.[138] It is unknown what significance the presence of the CRMP2ab has in
chronic SCI. It is possible that the presence of CRMP2ab could impinge on CRMP2’s role
in growth-cone collapse. Whether and how CRMP2ab is involved in inhibition of axonal
guidance after SCI is of interest for future studies. The CRMP family of proteins includes
CRMP 1, 2, 3, 4 and 5.

CRMP1-4 have high sequence homology (approximately

75%).[138] The homology may have contributed to some of the nonspecific binding that
was observed. No correlations were discovered with presence of CRMP2ab and level of
injury, completeness of injury, presence of comorbid conditions, skin ulcers, spasticity, sex
or age in post hoc analysis in the acute subjects. Five percent of healthy volunteers had
CRMP2ab, this is of unknown significance. Autoantibodies to CRMP-2 have been identified
in autoimmune retinopathy and cancer-associated retinopathy (melanoma, breast cancer
and lymphoma).[155] None of the enrolled subjects were known to have retinopathy or
cancer.
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The presence of GFAPab at 16 ± 7 days after SCI is a predictor of the development of
neuropathic pain.
Using a threshold of 36ng/mL of GFAPab in plasma has 74% sensitivity and 73%
specificity for predicting the development of neuropathic pain within 6 months of SCI.
GFAPab was not found to be diagnostic of neuropathic pain in the chronic patients, but
data indicate that higher levels of in GFAPab in the acute stage it is a fair predictor.
One potential method of preventing the development of GFAPab would be to inhibit
GFAP production and release into the circulation. There are medications that attenuate
neuropathic pain in rodent models that inhibit glial cells activation, propentofylline,
Ibudilast, and withaferin-A.[110, 241] Propentofylline inhibits GFAP production and was
shown to reduce neuropathic pain behaviors in part through its regulation of proinflammatory cytokines.[110] Propentofylline and ibudilast inhibit phosphodiesterase and
inhibit glial cell activation which has been correlated with reduced pain. [110] However, in
human pain studies ibudilast did not have a positive effect in an opioid-overuse headache
trial,[242] and propentofylline did not relieve pain in a post-herpetic neuralgia study.[243]
Withaferin-A or ashwagandha is a steroidal lactone that binds and inhibits GFAP that was
shown to have analgesic effect in rats.[192]

Additionally, reduction in GFAP protein

expression from clomipramine, a tricyclic antidepressant, was confirmed in mouse
astrocytes after it was identified via a screen of chemical libraries.[244] Clomipramine, has
been shown to reduce neuropathic pain in humans.[245]

C3 and C5 remained elevated through 16 ± 7 days after SCI.
Plasma levels of complement C3 and C5 levels were elevated after SCI through the
16 day time point. Serum complement elevation has been shown previously in human SCI
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at 2 weeks to 9 years post-SCI.[24] Complement is constitutively present in the systemic
circulation in its inactive form. Complement is activated early following trauma as part of
the initiation of the inflammatory cascade. C3a and C5a are released systemically after
complement system activation and exert pro-inflammatory effects. An increase of
complement C3 genes is characteristic of reactive A1 astrocytes (reactive A2 astrocytes
are neuroprotective and do not express C3); A1 astrocytes induce toxicity to synapses and
contribute to death of neurons and mature oligodendrocytes after acute CNS injury.[162]
After SCI, complement components are deposited in astrocytes, neurons, oligodendrocytes
and axons of the injured cord.[45] In mouse injury models, C3 was found at the injury site
within one hour peaking at 24 hours post-contusion.[246] Interestingly, C3 deficient mice
had better locomotor scores than wild-type contused mice (p<0.001) suggesting C3 has a
negative impact on motor function recovery. Additionally, there was more tissue
preservation and less demyelination in spinal cords of C3 deficient mice.

Here, the

determination of the presence of neuropathic pain was based on pain development within 6
months and therefore acute measurements of circulating complement in the early postinjury time period may not directly correlate.

Elevated complement may be one piece of

the diagnostic puzzle to indicate which individuals develop neuropathic pain.[22, 213]
However, the assumption that sequestration of complement due to GFAP or CRMP2
breakdown would be reflected as lower plasma C3 or C5 levels was not supported by the
data. An alternate explanation could be that trauma to the tissue caused an activation of
complement as part of an inflammatory reaction.

B. Weakness
There are several limitations to this study. First, the samples were collected at predetermined time periods, therefore peak levels may not be represented for each subject,
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and were likely not present in the chronic samples. There were 118 SCI patients to study,
but only 38 of them with samples available at the time observed to be the peak for the
group autoantibody levels.

A larger sample size could strengthen these results as

indicated in the power analysis performed using the CRMP2ab results discussed above.
Secondly, these studies are correlative and conclusions cannot be made on the
nature of the presence of autoantibody causing neuropathic pain.

If the presence of

GFAPab or CRMP2ab is found to be causal, removal of the autoantibody could be
explored as a preventive therapy. The effect of an autoantibody to GFAP or CRMP2 may
be from a direct antibody-antigen binding causing protein misfolding, or functional
interference with GFAP or CRMP2, or causing a decrease in availability of the GFAP or
CRMP2 protein. Spinal cord tissue pathology cannot be determined based on these
studies. Or the autoantibody may be contributing to pathology through increasing
inflammation.

Neuropathic pain may be caused by sprouting of pain fibers,

hyperexcitability, sensitization, chronic BSCB permeability and persistent inflammation.[25,
103, 109]

The presence of GFAPab and CRMP2ab may have contributed to the

development of neuropathic pain by supplementing any of these processes. Astrocytes
play an essential role in maintaining the BSCB. If GFAPab binds astrocytic GFAP it would
likely disrupt astrocytes function which could contribute to a perpetually permeable cord or
a change in the cytokines and immune cells migrating across the BSCB; this inflammatory
state could lead to neuropathic pain.[25, 160] If the GFAPab and CRMP2ab are formed in
response to proteins released from cells damaged after injury, it is possible that
autoantibody-induced damage occurs and once a threshold of nerve damage and
hyperexcitability has been reached the presence of the autoantibody is no longer
necessary for neuropathic pain to persist.
Third, while validation studies have confirmed the GFAPab and CRMP2ab
specificity, it is possible that the autoantibody after SCI may also be polyspecific. The
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autoantibody may cross-react with the GFAP or CRMP2 antigen; however, it may have
been developed in response to another agent.

Multiple examples can illustrate

polyspecificity, for instance, rheumatic fever is caused by anti-streptococcal antibodies
(produced after an infection) that cross-react with a cardiac tissue antigen.[247] Antibodies
to the Epstein-Barr virus have been shown to cross react with human heterogeneous
nuclear ribonucleoprotein L (a protein involved in the formation and function of mRNA)
related to identity of stretches of glycine-alanine repeats.[248]

Homology exists between

AQP4 and C. perfringens and overexpression of C. perfringens has been found in the
intestine of NMO patients, indicating it could behave as a molecular mimic.[170] Molecular
mimicry between Campylobacter jejuni which causes enteritis and ganglioside GM1
causing cross-reacting antibodies

is involved in the development of Guillain-Barre

syndrome (a demyelinating disease); anti-ganglioside GM1 has been identified in SCI.[16,
19, 249] These bacteria are found in the intestine, and GFAP is expressed in enteric glial
cells.

Enteric glial cells have a response similar to that of activated astrocytes under

inflammatory conditions.

They respond with an upregulation of GFAP, proliferate and

hypertrophy; additionally they propagate immune signaling by secretion of IL1β, IL6 and
TNFα, and expression of MHC class II molecules.[250]
In patients following trauma or severe injury intestinal bacteria can translocate
through the disrupted gut barrier and induce systemic infection.[251-253] Mouse models
have shown that pathological changes in the composition of the gut microbiome (“gut
dysbiosis”) cause immune dysregulation, neuroinflammation and exacerbate neurological
disorders.[170, 254-257] A SCI mouse study that induced gut dysbiosis via the delivery of
broad-spectrum antibiotics demonstrated that SCI-induced gut dysbiosis is associated with
gut-associated lymphoid tissue immune cell activation, and that dysbiosis hinders recovery
and worsens intra-spinal inflammation.[50] However, neuropathic pain was not evaluated in
these gut dysbiosis SCI mice. The intestinal microbiota of 30 complete SCI patients was
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compared to 10 healthy controls revealing that SCI patients had lower bacterial DNA
counts of numerous butyrate producing bacteria.[258] However, symptoms of infection,
inflammation or neuropathic pain were not evaluated. Butyrate producing bacteria play a
key role in maintaining gut barrier function.[258]
Homology between common intestinal bacteria and GFAP and CRMP2 was
explored as part of the present study. BLAST (National Center for Biotechnology
Information, U.S. National Library of Medicine) searches were performed for GFAP or
CRMP2 looking for homology to some specific, common intestinal bacteria such as
Campylobacter jejuni, Helicobacter pylori (both known to have structures that are
associated with the development of autoimmune conditions[259]), Escherichia coli,
Enterobacter, and the Campylobacter group. While an exhaustive search was not
performed, it is clearly evident that CRMP2 shares high homology to bacteria in the
Enterobacter family, suggesting molecular mimicry may be involved with the response
observed in the acute subjects. GFAP shares homology with bacteria searched, but to a
much lesser degree.

For instance, when searching the campylobacter group,

dihydroorotase [Campylobacter concisus] which is bacteria commonly associated with
irritable bowel disease, results indicated it has 43% homology with 28% identity to CRMP2.
A refined search to evaluate only the conserved domains of CRMP2 (to increase the
chance of homology) did not reduce the area to be searched for CRMP2.

GFAP

conserved domains include the filament head domain (4-66) and the filament (68-376).
Searching by the conserved domain of GFAP increased the percent homology.

For

example, searching the head domain against Enterobacteriaceae resulted in 65%
homology with 61% identity. This gram negative bacteria family includes Salmonella, E.
coli and Klebsiella. These results indicate that there is the possibility that the responses
seen in plasma may be related to homology to pathogens to which the patient was
previously exposed. Alternatively, concomitant inoculations with these pathogens could
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have contributed to autoantibody formation. Regardless of the whether or not the
autoantibody is polyspecific, it does not negate the fact that the presence of the
autoantibodies at the 16 day time point showed a 9.5 times increased risk of neuropathic
pain.

C. Model

The model suggests that the injury to the spinal cord causes damage to neurons
and axons, and that astrocytes and microglia are activated, CNS proteins are released into
the circulation and inflammation occurs.

There is increased vascular and BSCB

permeability and complement is activated exacerbating inflammation. Activated B cells
generate autoantibodies; these autoantibodies (CRMP2ab and GFAPab) may interfere with
normal cell function, damage tissue and perpetuate inflammation resulting in neuropathic
pain (Figure 34, 35).
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Figure 34. Model of the presence of autoantibodies at the SCI injury site

Figure 34. Model of the presence of autoantibodies at the SCI injury
site.
The injury to the spinal cord causes damage to neurons and axons,
astrocytes and microglia are activated, CNS proteins are released
into the circulation and inflammation occurs, there is increased
vascular and BSCB permeability and complement is activated
exacerbating

inflammation.

Activated

B

cells

generate

autoantibodies; these autoantibodies may interfere with normal cell
function, damage tissue and perpetuate inflammation resulting in
neuropathic pain.
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Figure 35. Overview Model
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This research makes two contributions.

It established a process for identifying

autoantibodies and it identified two autoantibodies that are associated with the
development of neuropathic pain within 6 months after SCI.

The work established a

process for identifying autoantibodies in human plasma. Using an unbiased approach,
patterns of change in immunoreactivity produced by SCI patients’ plasma were identified
by western blot. The potential antigens were separated using 2-D gel electrophoresis.
Areas with new or enhanced immunoreactivity were isolated, the corresponding gel spots
were excised and the proteins were identified using LC-MS/MS. The antigen candidates
were carefully confirmed as autoantigens causing the immunoreactivity.

Critically, the

capillary immunoassay blocking and competition studies revealed that non-specific binding
can occur. The identification of non-specific binding demonstrates the utility of using this
method over other methods which might not distinguish the specificity of binding.
The data indicates that there is potential for a diagnostic tool to differentiate patients
who may develop neuropathic pain within 6 months after SCI from those who do not by
assaying levels of GFAPab and CRMP2ab in combination with complement and other
potential factors. Additionally, autoantibodies are likely to be present that are associated
with other secondary pathologies. The identification of autoantibodies produced after SCI
may lead to new treatment targets or new prognostic indicators.

D. Future directions
GFAPab and CRMP2ab may be two of multiple autoantibodies that contribute to the
development of neuropathic pain.

Future studies will evaluate additional autoantibody

candidates and look at the possibility that adding to this panel of antibodies improves the
predictive value.
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E. Study impact in spinal cord injury

Results indicating the presence of GFAPab, and GFAP and/or CRMP2ab at 16 days
are associated with the development of neuropathic pain within 6 months after SCI builds
on experimental studies.

Experimental mouse studies demonstrated that SCI causes

autoantibody production and that autoantibodies impair recovery of function and worsen
tissue damage.[5, 9] In SCI, however they did not demonstrate an association with the
development of autoantibodies and the subsequent development of neuropathic pain. The
discovery of autoantibodies reactive to GFAP and CRMP2 in SCI patients may lead to the
development of new biomarkers for prediction of the development of neuropathic pain, and
importantly, if determined as causal, new treatments for SCI-related neuropathic pain.
Pain has a serious impact on the quality of life for SCI patients experiencing
neuropathic pain. Currently, there are no diagnostic tools available to predict who will
develop chronic neuropathic pain, nor are there fully effective therapies available to treat
this debilitating condition. Ultimately, the goal is that discovery of autoantibodies predictive
of pain will not only detect those patients in need of intervention, but may also identify new
areas of investigation that can create therapies to eliminate the onset of neuropathic pain
and its associated morbidity.
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APPENDIX

A. Protein A affinity columns
IgG purification was performed and affinity columns were created using recombinant
protein A to covalently crosslink the antibody in the plasma sample. BCA and optical
density measurements of washes and western blots and coomassie stained gels provided
confirmation of successful IgG purification and antibody crosslinking to Protein A. The
homogenized CNS tissue was applied the affinity column and the antigen/proteins were
eluted with glycine. The antigen was then run on a Coomassie gel and Western blot. The
eluted antigen was to be cut out of the Coomassie gel for identification by LC-MS/MS.
Appendix Figure 1 shows GFAP eluted from the protein A affinity column made with custom
anti-GFAP. Columns made with whole serum were not successful. Therefore, the 2-D gel
approach was taken.
Methods
Antibody purification Antibody purification was performed with a Melon Gel IgG
Spin Purification kit (Thermo Scientific, Rockford, IL).

The kit binds high abundance

proteins like albumin and transferrin using a mild buffer at physiological pH. It is aminefree. Columns were prepared with gel slurry (200µl) centrifuged and washed twice with 120
µl of purification buffer. Samples diluted with gel purification buffer (50µl sample: 450µl
buffer) were added to the column and mixed for 5 minutes. Purified antibody was tested in
a western blot, on a coomassie blue stain gel and after confirmation of protein it applied to
the protein A affinity column.
Protein A affinity column Purified IgG was applied to protein A affinity
columns(Pierce Protein A IgG Plus Orientation, Thermo Scientific, Rockford, IL) to crosslink
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the antibody to protein A agarose. Purified IgG was diluted with antibody binding/wash
buffer (1:1) and loaded on to equilibrated columns. The resin was re-suspended and mixed
at room temperature for one hour. The resin was allowed to settle and solution pass
through was collected for analysis of binding efficiency. Because binding efficiency was
insufficient as measured by BCA and spectrophotometry, the process was repeated, but
instead the resin and sample were incubated overnight at -4°C. Binding efficiency was
confirmed with spectrophotometry. The columns were washed and Crosslinking buffer was
prepared with DSS dissolved in DMSO and immediately applied to the antibody-bound
column. The column was incubated for one hour for one hour on a rotator. The resin was
washed with crosslinking buffer and then blocked with blocking buffer to block any
remaining non-reacted NHS-ester groups.

Resin was re-suspended and mixed.

IgG

elution buffer was applied to elute any IgG that was not covalently bound to protein A. The
column was washed and completed and stored in a 0.02% sodium azide PBS solution at
4°C for future use. Samples coming off the column at each step were saved and efficiency
was evaluated by spectrophotometry.
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Results

Coomassie gel (left) and western blot (right) of Glial Fibrillary Acidic Protein
(GFAP) antibody affinity column (GFAP, MW 50kD, arrow).

Affinity columns

(AminoLink) for GFAP were created. Starting brain extract (50ul plus 450ul PBST) was
incubated on the column. Flow through shows the brain proteins that were not retained
on the column. Glycine 1 was the first elution from the column showing the antigen
(GFAP) that was bound to the anti-GFAP column. Western blot was probed with a
custom anti-GFAP primary antibody (1:6000) and alkaline phosphatase secondary antirabbit antibody. As anticipated, GFAP antigen is visible on the western blot that was
probed with custom anti-GFAP (arrow). Serum elution from healthy volunteer serum
was not expected to and did not show GFAP. When the columns were made using
purified IgG from patient plasma as the antibody bound to the protein A agar, the
proteins came off in the flow through, but did not come off on the glycine elution
suggesting binding was not strong enough (not shown).
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B. Immunohistochemistry (IHC) performed on monkey brain tissue.
Immunohistochemistry on monkey
brain tissue. Monkey brain tissue
stained with human plasma taken
16±7 days post-SCI (top). Faint
staining of astrocytes can be seen.
The same tissue probed with a
custom anti-GFAP antibody
showing reactive astrocytes
(bottom). Similar to Ishida et al.,
the autoantibody was not clearly
detectable using IHC. As
suggested by them, this may be
that the epitope of the antigen is
concealed in situ because of
intermolecular or intramolecular
conformation. [195]
[195]
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